Document:

Document

PAYPAL HOLDINGS, INC. 
EXECUTIVE CHANGE IN CONTROL AND SEVERANCE PLAN 
AND 
SUMMARY PLAN DESCRIPTION 
As Amended and Restated, Effective as of September 27, 2021
1.PURPOSE OF THE PLAN
The purpose of the PayPal Holdings, Inc. Executive Change in Control and Severance Plan (the “Plan”) is to encourage the full attention and dedication of certain eligible executives of the Company or any of its participating subsidiaries, and to provide severance benefits to such eligible executives upon their separation from the Company or any of its participating subsidiaries under the conditions described herein.  The Plan is not intended to be an “employee pension benefit plan” or “pension plan” within the meaning of Section 3(2) of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”).  Rather, the Plan is intended to be an unfunded “top hat” welfare benefit plan subject to ERISA.  

This document serves as both the Plan document and summary plan description.  The Plan was adopted effective as of December 31, 2019, and applies to Covered Terminations occurring on or after January 1, 2020.  The Plan is amended and restated effective as of July 1, 2021. The payment of severance benefits to any Participant who had a Covered Termination prior to January 1, 2020 will be determined in accordance with the terms of the applicable plan or individual agreement in effect at the time of such Covered Termination.  The Plan replaces any and all prior policies, plans, and arrangements (whether written or unwritten) with Eligible Participants, to the extent that such policies, plans, and arrangements provide for payments to be made after termination of employment directly by an Employer, other than pursuant to an Employer retirement plan or deferred compensation plan.  

2.DEFINITIONS
(a)Accrued Benefits – means prompt payment by the Company to an Eligible Participant of (a) any accrued but unpaid base salary through the last day of employment, (b) any unreimbursed expenses incurred through the last day of employment subject to the Eligible Participant’s prompt delivery to the Company of all required documentation of such expenses pursuant to applicable Employer policies and (c) all other vested payments, benefits or fringe benefits to which the Eligible Participant is entitled under the terms of any applicable compensation arrangement or benefit, equity or fringe benefit plan or program or grant (excluding any other severance plan, policy or program) of the Company in accordance with the terms of such arrangement, plan, program or grant. 

(b)Board – means the Board of Directors of the Company. 

(c)Cause – means (a) an Eligible Participant’s failure to attempt in good faith to substantially perform his or her assigned duties, other than failure resulting from his or her death or incapacity due to physical or mental illness or impairment, which is not remedied within 30 days after receipt of written notice from the Company specifying such failure; (b) an Eligible Participant’s indictment for, conviction of or plea of nolo contendere to any felony (or any other crime involving fraud, dishonesty or moral turpitude); or (c) an Eligible Participant’s commission of an act of fraud, embezzlement, 

misappropriation, willful misconduct, or breach of fiduciary duty against the Company, except good faith expense account disputes.

(d)Change in Control – means a “change in control” as such term is defined in the Equity Incentive Award Plan. The Compensation Committee will have full and final authority, which will be exercised in its discretion, to determine conclusively whether a Change in Control has occurred pursuant to the above definition, and the date of the occurrence of such Change in Control and any incidental matters relating thereto; provided, that such "change in control" is a “change in control event” as defined in Treasury Regulation § 1.409A-3(i)(5). 

(e)Change in Control Period – means the period that begins 90 days prior to, and ends 24 months following, a Change in Control. 

(f)COBRA – means the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended,

(g)Code – means the Internal Revenue Code of 1986, as amended.

(h)Company – means PayPal Holdings, Inc. or, after a Change in Control, any Successor Entity.

(i)Company Equity Award – means an incentive award granted to an Eligible Participant and relating to shares of common stock of the Company (“Stock”) or, after a Change in Control, the common equity of any Successor Entity, pursuant to the Equity Incentive Award Plan or otherwise, including without limitation any award of stock options, performance-based restricted stock units or restricted stock units. 

(j)Compensation Committee – means the Compensation Committee of the Board.

(k)Disability, or to become Disabled – means an Eligible Participant’s employment with the Company terminates because (i) the Eligible Participant is unable to return to work while receiving benefits under the Company’s long term disability plan (the “LTD Plan”),  or (ii) if the Eligible Participant is not covered by the LTD Plan, he or she is unable to return to work due to a long-term disability that would qualify for benefits under the LTD Plan, as determined by the Plan Administrator or a third-party designated by the Plan Administrator; provided that the Eligible Participant (x) requests in writing continued vesting due to such disability within 30 days of the date his or her employment terminates, (y) provides any requested supporting documentation, and (z) receives the Company’s written consent to such treatment.

(l)Eligible Participant – means any employee of the Company or one of its subsidiaries who meets all of the eligibility requirements set forth in Section 4 (Eligibility), and who holds a position at or above the level of Vice President. 

(m)Employer – means the Company and any U.S. subsidiary or U.S. affiliate of the Company whose voting equity is, directly or indirectly, more than fifty percent (50%) owned by the Company. 
2

(n)Equity Incentive Award Plan – means the Company’s Amended and Restated 2015 Equity Incentive Award Plan, as amended from time to time, or any successor thereto. 

(o)ERISA – means the Employee Retirement Income Security Act of 1974, as amended.

(p)Good Reason – has the meaning set forth in the applicable Appendix hereto.  In order to resign for Good Reason, (a) the Eligible Participant must provide written notice to the Company of such Good Reason event(s) within 60 days from the first occurrence of such Good Reason event(s), following which the Company will have 30 days to cure such event, and (b) to the extent the Company has not cured such Good Reason event(s) during the 30-day cure period, the Eligible Participant must terminate his or her employment for Good Reason no later than 60 days following the occurrence of such Good Reason event(s) by providing the Company 30 days’ prior written notice of termination, which may run concurrently with the Company’s cure period stated above. 

(q)Individual Agreement – means an individual employment letter agreement or other agreement between an employee and an Employer that provides for the payment of severance benefits outside of the Plan upon a qualifying termination of employment.

(r)Plan Administrator – means the Compensation Committee or such other person or committee appointed from time to time by the Compensation Committee to administer the Plan. 

(s)Qualifying Termination – has the meaning set forth in the applicable Appendix hereto.

(t)Qualifying Retirement – has the meaning set forth in the applicable Appendix hereto. 

(u)Separation Date – means the effective date of an Eligible Participant’s Separation from Service.

(v)Separation from Service – means, except as provided in subsections (a) and (b) below, an employee’s termination from employment (whether by retirement or resignation from or discharge by the Company). 

i.A Separation from Service will be deemed to have occurred if an employee and the Company reasonably anticipate, based on the facts and circumstances, that the employee will not provide any additional services for an Employer after a certain date; provided, however, that if any payments or benefits that may be provided under the Plan constitute deferred compensation within the meaning of Section 409A of the Code, a Separation from Service also will be deemed to have occurred in the event that the level of bona fide services performed by the employee after a certain date will permanently decrease to no more than 20% of the average level of bona fide services performed by the employee over the immediately preceding 36-month period. 

ii.Notwithstanding the foregoing, for purposes of the Plan, an employee’s employment relationship is treated as continuing intact while the employee is on military leave, sick leave, 
3

or other bona fide leave of absence if the period of such leave does not exceed six months, or if longer, so long as the individual retains a right to reemployment with an Employer under an applicable statute or by contract. For purposes of the Plan, a leave of absence constitutes a bona fide leave of absence only if there is a reasonable expectation that the employee will return to perform services for an Employer. If the period of leave exceeds six months and the employee does not retain a right to reemployment under an applicable statute or by contract, the employment relationship is deemed to terminate on the first date immediately following such six-month period due to such employee’s Disability, in which case such employee will not be an Eligible Participant except as otherwise provided in Section 4 of the Plan. 
The definition of “Separation from Service” will at all times be interpreted in accordance with the terms of Treasury Regulations Section 1.409A-1(h) and any guidance issued thereunder. 

(w)Severance Pay Benefits – means the cash severance benefit determined in accordance with the applicable Appendix hereto, and payable in accordance with Section 5 (Severance Benefits). 

(x)Successor Entity – means “successor entity” as such term is defined in the Equity Incentive Award Plan.
3.GENERAL RULES
(a)Effective Date. The Plan is effective as of December 31, 2019, as amended and restated effective July 1, 2021, and will replace all prior plans, programs, Individual Agreements and arrangements providing change in control or severance type benefits to Eligible Participants, including without limitation the PayPal Holdings, Inc. SVP and Above Standard Severance Plan and the PayPal Holdings, Inc. Change in Control Severance Plan for Key Employees, each of which will terminate as of the Effective Date, and any offer letter or other agreement between the Company or any of its affiliates, on the one hand, and such Eligible Participant, on the other hand, in accordance with the Participation Agreement executed by such Eligible Participant.

(b)Amendment and Termination. The Company is under no obligation to continue the Plan for any period of time. The Plan Administrator, in its sole discretion, reserves the right to modify, amend or terminate the Plan (including the benefits set forth in the appendices of the Plan), in whole or in part, at any time and for any or no reason with respect to any employee or all employees at any time prior to his, her or their receipt of any severance benefits; provided, however, that in no event will the Plan be terminated, or modified or amended in any manner that is adverse to (i) any Eligible Participants at any time during the Change in Control Period or (ii) any Eligible Participant who is receiving payments or benefits under the Plan as a result of a Qualifying Termination. For the avoidance of doubt, the foregoing prohibition does not and will not require that all Eligible Participants receive the same severance benefits that the Plan Administrator may in its sole discretion choose to provide to any given Eligible Participant.

(c)Benefits Non-Assignable. Benefits under the Plan may not be anticipated, assigned or alienated; provided that if an Eligible Participant becomes eligible for a benefit and dies before payment is made, such Eligible Participant’s heirs will be entitled to the payment. 
4

(d)Governing Laws. The Plan is intended to be a “top hat plan” and will be interpreted, administered and enforced in accordance with ERISA.  It is expressly intended that ERISA preempt the application of state laws to the Plan to the maximum extent permitted by Section 514 of ERISA.  To the extent that state law is applicable, the statutes and common law of the State of Delaware will apply. Except as may otherwise be provided in an applicable Appendix hereto, the parties irrevocably and unconditionally submit to the jurisdiction and venue of U.S. District Court for the District of Delaware for purposes of any suit, action or other proceeding arising out of, or relating to or in connection with the Plan. 

(e)No Right to Continued Employment. Neither the Plan nor any action taken with respect to it confers upon any person the right to continue in the employ of the Company or any of its subsidiaries or affiliates. Employees will continue to be employed “at-will,” as defined under applicable law. 

(f)Funding. The Company or one of its affiliates will make all payments under the Plan, and pay all expenses of the Plan, from its general assets. Nothing contained in the Plan gives any Eligible Participant or any other person any right, title, or interest in any property of the Company or any of its affiliates. 

(g)Severability. The provisions of the Plan are severable. If any provision of the Plan is deemed legally or factually invalid or unenforceable to any extent or in any application, then the remainder of the provisions of the Plan, except to such extent or in such application, will not be affected, and each and every provision of the Plan will be valid and enforceable to the fullest extent and in the broadest application permitted by law.
4.ELIGIBILITY
(a)General Eligibility. The benefits under the Plan are limited to employees of an Employer who satisfy each of the following conditions, as determined by the Plan Administrator in its sole discretion: 

i.The employee is classified as an Eligible Participant;  
ii.The employee is terminated due to a Qualifying Termination; 
iii.The employee is actively at work through the last day of work designated by an Employer, unless (A) the employee is absent due to an approved absence from work (including leave under the Family and Medical Leave Act) or (B) unless otherwise designated by his or her written agreement with the Employer; 
iv.The employee executes and does not revoke a Separation Agreement (the “Separation Agreement”) and a waiver and general release of claims (the “Release”), each in the form and within the period specified by Plan Administrator or its delegate; and
v.The employee returns all property of any Employer and settles all expenses owed to the Employer and any of its subsidiaries or affiliates.

(b)Exclusions from Eligibility. Unless the Plan Administrator provides otherwise in writing, the following employees are not eligible to participate in the Plan: 

5

i.Any employee who is eligible to receive severance payments and/or benefits under an Individual Agreement from and after the Effective Date; 
ii.In the case of an involuntary termination of employment, any Eligible Participant who terminates employment prior to the stated Separation Date as set forth in his or her Separation Agreement; and 
iii.Any Eligible Participant whose employment is terminated for any of the following reasons:  
•Resignation or other voluntary termination of employment, other than for Good Reason or a Qualifying Retirement, as provided in the Plan; or
•Termination for Cause.
5.SEVERANCE BENEFITS
(a)Accrued Benefits. The Company (or one of its affiliates) will make payment or otherwise provide all Accrued Benefits when due. Such obligation will not be subject to the Eligible Participant’s execution of a Separation Agreement or Release.

(b)Severance Pay Benefit. The Company will pay to each Eligible Participant a Severance Pay Benefit in an amount determined in accordance with the applicable Appendix, subject to the reductions set forth below; provided, however, that the Plan Administrator, in its sole discretion and on a case-by-case basis, may increase (but not decrease, except as provided below) such Severance Pay Benefit payable to an Eligible Participant.

(c)Reduction of Severance Pay Benefit. Unless an Employer, in its sole discretion, provides otherwise in writing, the amount of the Severance Pay Benefit payable to an Eligible Participant will be reduced as follows: 
i.In the event that an Employer triggers Worker Adjustment and Retraining Notification Act (“WARN”) (or other similar federal or state statute), any Severance Pay Benefit will be offset by any amount paid pursuant to WARN.  If the Employer provides pay-in-lieu-of-notice to the Eligible Participant instead of advance notice of his or her termination of employment in accordance with the requirements of WARN, then the amount of such Eligible Participant’s Severance Pay Benefit will be reduced (but not below zero) by any amount required to be paid or otherwise owing to the employee under WARN.
ii.An Eligible Participant’s Severance Pay Benefit will be reduced by any outstanding debt owed by the employee to the Company or any of its affiliates, where permitted by law, including but not limited to loans granted by an Employer or any advanced commissions, bonuses, vacation pay, salary and/or expenses. 
iii.In addition, an Eligible Participant’s Severance Pay Benefit will be inclusive of, and not in addition to, any severance or termination payments that may be required to be paid by statute or other governmental mandate of applicable laws. 
iv.In the event of a Change in Control, where an accounting firm designated by the Company determines that (x) the aggregate amount of the payments and benefits that (but for the application of this paragraph) would be payable to an Eligible Participant under the Plan and/or any other plan, policy or arrangement of the Company or of its affiliates, exceeds (y) the greatest amount of payments and benefits that could be paid or provided to the Eligible Participant without giving rise to any liability for any excise tax imposed by Section 4999 of 
6

the Code (the “Excise Tax”), then the Eligible Participant will either (1) pay the Excise Tax and receive all such payments and benefits as may be payable to him or her, or (2) only receive the aggregate amount of such payments and benefits payable or to be provided to the Eligible Participant that would not exceed the greatest amount of payments and benefits that could be paid or provided to the Eligible Participant without giving rise to any liability for any Excise Tax (such reduced amount of payments and benefits, the “Reduced Benefit Amount”), whichever of the two courses of action in clause (1) or clause (2) hereof produces the greatest after-tax benefit to the Eligible Participant. In the event the Reduced Benefit Amount is paid, the reduction in such payments or benefits pursuant to the immediately preceding sentence will be made in the following order: first, by reducing the Severance Pay Benefit; second, by reducing any health premium payments or reimbursements provided pursuant to the Plan; third, by reducing the accelerated vesting of any then outstanding performance-based Company Equity Awards in reverse order of their scheduled vesting dates; and fourth, by reducing the accelerated vesting of any then outstanding time-vested Company Equity Awards, in reverse order of their scheduled vesting dates. 

(d)Payment of Severance Pay Benefit.  The Company will pay the Severance Pay Benefit in a lump sum cash payment. Payment will be made as soon as practicable after the later of the Eligible Participant’s Separation Date or the date on which such employee’s Separation Agreement and/or Release become effective (i.e., the date the Separation Agreement and/or Release cannot be revoked by the employee), but not later than 60 days following the Eligible Participant’s Separation Date; provided, that if the Separation Date occurs within the 90-day period prior to the date of a Change in Control, then the amount of the Severance Pay Benefit payable in connection with the Change in Control will be paid within 60 days after the date of the Change in Control and will be reduced by any Severance Pay Benefit paid prior to such payment date under the Plan. 

(e)Annual Incentive Plan. If an Eligible Participant is eligible to participate in the Annual Incentive Plan of the Company or an applicable successor plan (the “AIP”) for the year immediately prior to the year in which he or she experiences a Separation from Service eligible for benefits under the Plan, and the Separation from Service occurs prior to the payment of bonuses under the AIP with respect to such prior year, the Eligible Participant will be eligible to receive a bonus based on and subject to the attainment of applicable performance objectives for such year; provided that for such purpose the Eligible Participant will be deemed to have satisfied any individual performance component of such bonus at the target level.  Any AIP-related payment or settlement of equity pursuant this paragraph will be in accordance with the applicable terms of the AIP and will occur on the date that participants in the AIP receive their bonuses in respect of the applicable fiscal year.  In addition, an Eligible Participant will be eligible to receive an amount equal to a prorated portion of the Eligible Participant’s AIP bonus in respect of the fiscal year of the Company in which his or her Separation Date occurs, with the performance conditions attained or deemed attained as set forth in the applicable Appendix hereto.   The Company will pay such amount in a lump sum not later than 21⁄2 months after the last day of the applicable fiscal year.

(f)Health Benefits.  Each Eligible Participant who participates in a health plan of the Company or its affiliate and who elects to continue to participate in such plan under COBRA will be eligible for 
7

continued health benefits or a cash payment in lieu of such benefits, as determined at the discretion of the Plan Administrator, as set forth in the applicable Appendix hereto.  The Company will pay or reimburse such Eligible Participant for a portion of the premium cost incurred for each month of coverage, as set forth in the applicable Appendix hereto.  

(g)Company Equity Awards.  Each Company Equity Award held by an Eligible Participant and outstanding as of such Eligible Participant’s Separation Date will be treated in the manner set forth in the applicable Appendix hereto. 

(h)Other Benefits.  The Company or one of its affiliates will provide the Eligible Participant with any other benefits (if any) to the extent set forth in the applicable Appendix hereto.

(i)Withholding. The Company or one of its affiliates will withhold such amounts from payments under the Plan as it determines necessary or appropriate to fulfill any federal, state or local wage or compensation withholding requirements.
6.ADMINISTRATION OF THE PLAN
The Plan Administrator will have sole authority and discretion to administer and construe the terms of the Plan. Without limiting the generality of the foregoing, the Plan Administrator will have the following powers and duties: 
•To make and enforce such rules and regulations as it deems necessary or proper for the efficient administration of the Plan; 
•To amend and terminate the Plan in accordance with Section 3;
•To interpret the Plan, its interpretation thereof to be final and conclusive on all persons for purposes of the Plan;
•To decide all questions concerning the Plan, including the eligibility of any person to participate in, and receive benefits under, the Plan; and
•To appoint and/or retain such employees, agents, counsel, accountants, consultants and other persons as may be required to assist in administering the Plan.

7.CLAIMS PROCEDURE
The Plan Administrator reviews and authorizes payment of severance benefits for those employees who qualify under the provisions of the Plan. No claim forms need be submitted. Questions regarding payment of severance benefits under the Plan should be directed to the Plan Administrator. 
If an employee believes he or she is not receiving severance payments and benefits hereunder which are due, the employee should file a written claim for the benefits with the Plan Administrator. A decision on whether to grant or deny the claim will be made within 90 days following receipt of the claim. If more than 90 days is required to render a decision, the employee will be notified in writing of the reasons for delay. In any event, however, a decision to grant or deny a claim will be made by not later than 180 days following the initial receipt of the claim. 
If the claim is denied, in whole or in part, the employee will receive a written explanation containing the following information: 
•The specific reason(s) for the denial, including a reference to the Plan provisions on which the denial is based;
8

•A description of any additional material or information necessary for the employee to perfect the claim and an explanation of why such material or information is necessary; and
•A description of the Plan’s review procedures and the time limits applicable to such procedures, including a statement of the employee’s right to bring a civil action under Section 502(a) of ERISA following an adverse determination on review.
If the employee wishes to appeal this denial, the employee may write within 60 days after receipt of the notification of denial. The claim will then be reviewed by the Plan Administrator, and the employee will receive written notice of the final decision within 60 days after the request for review. If more than 60 days are required to render a decision, the employee will be notified in writing of the reasons for delay. In any event, however, the employee will receive a written notice of the final decision within 120 days after the request for review. 
As part of the Plan’s appeal process, the employee will be afforded: 
•The opportunity to submit written comments, documents, records, and other information relating to the claim for benefits;
•Upon request and free of charge, reasonable access to, and copies of, all documents, records and other information relevant to the employee’s claim for benefits; and
•A review that takes into account all comments, documents, records and other information submitted by the employee relating to the claim, without regard to whether such information was submitted or considered in the initial benefit determination.
If the decision on appeal is upheld, in whole or in part, the employee will receive a written explanation containing the following information: 
•The specific reason(s) for the decision, including a reference to the Plan provisions on which the decision is based;
•A statement that the employee is entitled to receive, upon request and free of charge, reasonable access to, and copies of all documents, records and other information relevant to the employee’s claim for benefits; and
•A statement of the employee’s right to bring an action under Section 502(a) of ERISA.
No legal action for benefits under the Plan may be brought unless the action is commenced within one year from the date of the final decision on appeal has been made. No person may bring an action for any alleged wrongful denial of Plan benefits in a court of law unless the claims procedures set forth above are exhausted and a final determination is made. If the employee or other interested person challenges a decision, a review by the court of law will be limited to the facts, evidence and issues presented during the claims procedure set forth above. Facts and evidence that become known to the employee or other interested person after having exhausted the claims procedure must be brought to the attention of the Plan Administrator for reconsideration of the claims determination. Issues not raised with the Plan Administrator will be deemed waived. 

8.ARBITRATION
Any and all disputes under, in connection with or with regards to the Plan must be arbitrated. Notwithstanding the prior sentence, the obligation to arbitrate does not apply to any claim required by law to be resolved in a forum other than arbitration, which claims shall be resolved in the appropriate forum as required by the laws then in effect. All arbitration related to this Plan shall be conducted by a neutral arbitrator through Judicial Arbitration and Mediation Services, Inc. (“JAMS”) in accordance the then current JAMS Employment Arbitration Rules and Procedures. A copy of the current JAMS rules can be found at www.jamsadr.com/rules-employment-arbitration.
 
9

9.SECTION 409A
Notwithstanding anything contained in the Plan to the contrary, to the maximum extent permitted by applicable law, no employee will have a legally binding right to payments under the Plan unless and until amounts are actually paid to them.  To the extent that an employee is deemed to have a legally binding right to a payment under the Plan, then amounts payable under the Plan will be made in reliance upon Treasury Regulation Section 1.409A-1(b)(9) (Separation Pay Plans) or Treasury Regulation Section 1.409A-1(b)(4) (Short-Term Deferrals) and exempt from Section 409A of the Code as a result of such reliance. Each payment to which an employee is entitled under the Plan will be considered a separate and distinct payment. In addition, (i) no amount payable hereunder will be payable unless the employee’s termination of employment constitutes a Separation from Service and (ii) if the employee is deemed at the time of his or her Separation from Service to be a “specified employee” for purposes of Section 409A(a)(2)(B)(i) of the Code, then to the extent delayed commencement of any portion of the termination benefits to which Eligible Participant is entitled under the Plan is required in order to avoid a prohibited distribution under Section 409A(a)(2)(B)(i) of the Code, such portion of the employee’s termination benefits will not be provided to the employee prior to the earlier of (A) the expiration of the six-month period measured from the Eligible Participant’s Separation Date or (B) the date of the employee’s death. Upon the earlier of such dates, all payments deferred pursuant to this Section 8 will be paid in a lump sum to the employee without interest, and any remaining payments due under the Plan will be paid as otherwise provided. The determination of whether the employee is a “specified employee” for purposes of Section 409A(a)(2)(B)(i) of the Code as of the time of his or her Separation from Service will be made by the Company in accordance with the terms of Section 409A of the Code (including without limitation Treasury Regulation Section 1.409A-1(i) and any successor provision thereto). To the extent applicable, if payment of an amount under the Plan could be paid in one of two calendar years subject to the delivery of a Separation Agreement and it is determined that payment of such amount in the earlier of such two years could constitute noncompliance with Section 409A of the Code, then such amount will be paid in the later of such two years. 

10.STATEMENT OF ERISA RIGHTS
Eligible Participants in the Plan are entitled to certain rights and protections under ERISA. ERISA provides that all plan Eligible Participants will be entitled to, as applicable: 
•Examine, without charge, at the Plan Administrator’s office and at other specified locations, such as worksites, all documents governing the plan and a copy of the latest annual report (Form 5500 Series) filed by the plan with the U.S. Department of Labor and available at the Public Disclosure Room of the Employee Benefits Security Administration.
•Obtain, upon written request to the Plan Administrator, copies of documents governing the operation of the plan and copies of the latest annual report (Form 5500 Series) and updated summary plan description. The administrator may make a reasonable charge for the copies.
•Obtain a complete list of the Employers sponsoring the Plan upon written request to the Plan Administrator.
•Receive a summary of the Plan’s annual financial report, if any. The Plan Administrator is required by law to furnish each Eligible Participant with a copy of this summary annual report.

Prudent Actions by Plan Fiduciaries 
In addition to creating rights for plan Eligible Participants, ERISA imposes duties upon the people who are responsible for the operation of the employee benefit plan. The people who operate the Plan, called “fiduciaries” of the Plan, have a duty to do so prudently and in the interest of all Plan Eligible Participants and beneficiaries. No one, including any Employer, any union, or any other person, may fire an employee 
10

or otherwise discriminate against him or her in any way to prevent them from obtaining a benefit under the Plan or exercising their rights under ERISA. 

Enforce Your Rights 
If an employee’s claim for a severance benefit is denied or ignored, in whole or in part, he or she has a right to know why this was done, to obtain copies of documents relating to the decision without charge, and to appeal any denial, all within certain time schedules. 
Under ERISA, there are steps an employee can take to enforce the above rights. For instance, if he or she requests a copy of plan documents or the latest annual report from the plan and does not receive them within 30 days, he or she may file suit in a Federal court. In such a case, the court may require the Plan Administrator to provide the materials and pay him or her up to $110 a day until he or she receives the materials, unless the materials were not sent because of reasons beyond the control of the administrator. If an employee has a claim for benefits which is denied or ignored, in whole or in part, he or she may file suit in a state or Federal court. In addition, if he or she disagrees with the Plan’s decision or lack thereof concerning the qualified status of a domestic relations order or a medical child support order, he or she may file suit in Federal court. If it should happen that Plan fiduciaries misuse the Plan’s money, or if an employee is discriminated against for asserting his or her rights, he or she may seek assistance from the U.S. Department of Labor, or may file suit in a Federal court. The court will decide who should pay court costs and legal fees. If an employee is successful, the court may order the person he or she has sued to pay these costs and fees. If the employee loses, the court may order him or her to pay these costs and fees, for example, if it finds the claim is frivolous. 

11.ASSISTANCE WITH QUESTIONS
If an employee has any questions about the Plan, he or she should contact the Plan Administrator. If an employee has any questions about this statement or about his or her rights under ERISA, or if the employee needs assistance in obtaining documents from the Plan Administrator, the employee should contact the nearest office of the Employee Benefits Security Administration, U.S. Department of Labor, listed in the telephone directory or the Division of Technical Assistance and Inquiries, Employee Benefits Security Administration, U.S. Department of Labor, 200 Constitution Avenue N.W., Washington, D.C. 20210. An employee may also obtain certain publications about his or her rights and responsibilities under ERISA by calling the publications hotline of the Employee Benefits Security Administration. 

11

ADMINISTRATIVE INFORMATION 
REQUIRED BY ERISA 
 
									
			
	Plan Sponsor and Plan Administrator, including address and telephone:		PayPal Holdings, Inc.
Compensation Committee of the
PayPal Holdings, Inc. Board of Directors
2211 North First Street
San Jose, CA 95131
(408) 967-7000

		
	Name and address of person designated as agent for service of process:		Kausik Rajgopal
EVP, Chief Human Resources Officer
PayPal Holdings, Inc.
2211 North First Street
San Jose, CA 95131
(408) 967-7000

		
	Basis on which Plan records are kept:		Calendar year - January 1 to December 31
		
	Type of Plan:		Unfunded welfare benefit severance plan
		
	EIN:		47-2989869

 

12

APPENDIX A 
SEVERANCE BENEFITS (CEO AND EVPS)
Under the Plan, Eligible Participants serving as the Chief Executive Officer of the Company, or as an Executive Vice President of the Company, are entitled to the severance benefits set forth in this Appendix A, based on their employment classification as of the date of termination, which will be paid or provided in accordance with the terms and conditions of the Plan to which this Appendix A is attached. The definitions of capitalized terms defined in this Appendix A apply to Appendix A only, as specified herein.
13

Chief Executive Officer
						
	Outside of a Change in Control Period
	Qualifying Termination	“Qualifying Termination” will mean:
(a)involuntary termination by the Company for a reason other than Cause or Disability;
(b)resignation by the Eligible Participant due to Good Reason; or
(c)solely for purposes of the treatment of Company Equity Awards, death or Disability.
“Good Reason” will mean: 
(a)a material reduction in the Eligible Participant’s annual base salary; 
(b)a material reduction in the Eligible Participant’s annual target bonus opportunity; 
(c)a material reduction in the Eligible Participant’s authority, duties or responsibilities as Chief Executive Officer (which would include a failure to report to the Board); or 
(d)any material breach by the Company of the offer letter agreement between the Company and the Eligible Participant, as amended from time to time; in each case without such Eligible Participant’s written consent and subject to the notice and cure conditions set forth in the Plan.

	Severance Pay Benefit	Severance Pay Benefit will mean:
(a)Two times the sum of the Eligible Participant’s (i) annual rate of base salary immediately prior to the Separation Date (without regard to any reduction by the Company that gives rise to Good Reason) and (ii) target AIP bonus amount for the year in which the Separation Date occurs; and
(b)Prorated AIP bonus amount for the year in which the Separation Date occurs, based on the number of full months Eligible Participant was employed with the Company during the AIP performance period and the actual Company performance through the end of the AIP performance period and target level of individual performance, settled in the form provided for under the terms and conditions of the relevant AIP, including without limitation, AIP Shares, as defined in the relevant AIP, if applicable.

	Health Benefits	Pursuant and subject to the terms and conditions of the Plan, the Eligible Participant will be eligible for the reimbursement of COBRA health premiums or payment of health premiums, at COBRA rates, for 18 months after the Separation Date or, if shorter, until the Eligible Participant becomes covered under a group health plan maintained by a subsequent employer, or other health plans, such as Medicare.

						
	Company Equity Awards	Pursuant and subject to the terms and conditions of the Plan, the Eligible Participant will be eligible for the following Company Equity Award severance benefits:
(a)Time-Based Awards.  All Company Equity Awards that are unvested as of the date prior to the Eligible Participant’s Separation Date and vest solely based on the continued service of the Eligible Participant (i.e., time-vesting awards), will be treated as though immediately vested on the Eligible Participant’s Separation Date as to the portion of such Company Equity Awards that would have otherwise become vested pursuant to their regular vesting schedule prior to the 12-month anniversary of the Separation Date (or, in the case of a termination due to Disability, any Company Equity Awards granted to the Eligible Participant prior to July 1, 2021 that would have otherwise become vested pursuant to their regular vesting schedule prior to the 24-month anniversary of the Separation Date will be treated as though immediately vested on the Eligible Participant’s Separation Date and Company Equity Awards granted to the Eligible Participant on or after July 1, 2021 shall be eligible for continued vesting in accordance with Appendix B).  Any such Company Equity Awards granted to the Eligible Participant prior to July 1, 2021 will be settled through the vesting and issuance or delivery of shares of Stock within sixty (60) days after the Eligible Participant’s Separation Date and any such Company Equity Awards granted to the Eligible Participant on or after July 1, 2021 will be eligible to continue vesting in accordance with their original vesting schedule following the Eligible Participant’s Separation Date, in each case subject to an effective Separation Agreement (including the Release/Certification Requirements set forth in Appendix B) and Release; provided that to the extent such Company Equity Award is scheduled to vest more frequently than annually, any continued vesting date not falling on an anniversary of the grant date of such Company Equity Award shall be deemed to fall on the next following anniversary of such grant date.

(b)Performance-Based Awards.  All Company Equity Awards that are unvested as of the date prior to the Eligible Participant’s Separation Date and vest based on the achievement of performance targets over a given performance period, other than (i) the CEO PSU Award, described in paragraph (c), below, and (ii) any AIP Shares, will remain outstanding and eligible to vest, based solely on the achievement of the applicable Company performance targets for any performance period that ends prior to the 12-month anniversary of the Separation Date; and, following the end of the performance period, the Company will determine the number of shares subject to such Company Equity Awards earned based on actual Company achievement of the performance goals pursuant to the terms of the applicable award agreements, and such Company Equity Awards will be settled in accordance with the terms and conditions of the applicable award agreement on the date that similar awards held by other participants are settled; provided, that in the case of a termination due to Disability, such Company Equity Awards granted to the Eligible Participant prior to July 1, 2021 will become immediately vested, based on target achievement of the performance targets, on the Eligible Participant’s Separation Date 

15

						
		to the extent they are subject to a performance period that ends prior to the 24-month anniversary of the Separation Date and Company Equity Awards granted to the Eligible Participant on or after July 1, 2021 shall be eligible for continued vesting in accordance with Appendix B. All such Company Equity Awards will be settled through the vesting and issuance or delivery of shares of Stock within sixty (60) days after the applicable vesting date, subject to an effective Separation Agreement (including the Release/Certification Requirements set forth in Appendix B) and Release.

(c)     CEO PSU Award.  In the event any portion of the performance-based Company Equity Award that was granted on April 1, 2018 (the “CEO PSU Award”) is earned but unvested as of the Eligible Participant’s Separation Date, such portion of the CEO PSU Award will be treated as though immediately vested on the Eligible Participant’s Separation Date as to the portion of such CEO PSU Award that would have otherwise become vested pursuant to its regular vesting schedule prior to the 12-month anniversary of the Separation Date (or, in the case of a termination due to death or Disability, prior to the 24-month anniversary of the Separation Date).  The CEO PSU Award will be settled through the vesting and issuance or delivery of shares of Stock within sixty (60) days after the Eligible Participant’s Separation Date, subject to an effective Separation Agreement and Release.  For the avoidance of doubt, any portion of the CEO PSU Award that is unearned and unvested as of the Eligible Participant’s Separation Date will be forfeited and cancelled upon the Eligible Participant’s Separation Date.

For the avoidance of doubt, any continued vesting of Company Equity Awards pursuant to this section, other than Company Equity Awards that were outstanding prior to July 1, 2021 to the extent they were eligible for accelerated or continued vesting in accordance with this section as in effect prior to July 1, 2021, shall be subject to the Eligible Participant satisfying the Release/Certification Requirements set forth in Appendix B.

16

Chief Executive Officer
						
	Within a Change in Control Period
	Qualifying Termination	“Qualifying Termination” will mean:
(a)involuntary termination by the Company for a reason other than Cause or Disability;
(b)resignation by the Eligible Participant due to Good Reason; or
(c)solely for purposes of the treatment of Company Equity Awards, death or Disability.
“Good Reason” will mean: 
(a)a material reduction in the Eligible Participant’s annual base salary; 
(b)a material reduction in the Eligible Participant’s annual target bonus opportunity; 
(c)a material reduction in the Eligible Participant’s authority, duties or responsibilities as Chief Executive Officer (which would include a failure to report to the board of directors of the Successor Entity) or the failure of the Eligible Participant to serve as Chief Executive Officer of a publicly traded corporation; or
(d)any material breach by the Company of the offer letter agreement between the Company and the Eligible Participant, as amended from time to time; in each case without such Eligible Participant’s written consent and subject to the notice and cure conditions set forth in the Plan.

	Severance Pay Benefit	Severance Pay Benefit will mean:
(a)Two times the sum of the Eligible Participant’s (i) annual rate of base salary immediately prior to the Separation Date (without regard to any reduction by the Company that gives rise to Good Reason) and (ii) target AIP bonus amount for the year in which the Separation Date occurs; and
(b)Prorated AIP bonus amount for the year in which the Separation Date occurs, based on the number of full months Eligible Participant was employed with the Company during the AIP performance period and the actual Company performance through the end of the AIP performance period and target level of individual performance, settled in the form provided for under the terms and conditions of the relevant AIP, including without limitation, AIP Shares, as defined in the relevant AIP, if applicable.

	Health Benefits	Pursuant and subject to the terms and conditions of the Plan, the Eligible Participant will be eligible for a lump sum payment of 24 months of health premiums, at COBRA rates, to be paid within sixty (60) days following the Separation Date.

17

						
	Company Equity Awards	Pursuant and subject to the terms and conditions of the Plan, the Eligible Participant will be eligible for the following Company Equity Award severance benefits:
(a)Time-Based Awards.  All Company Equity Awards that are unvested as of the date prior to the Eligible Participant’s Separation Date and vest solely based on the continued service of the Eligible Participant (i.e., time-vesting awards), will be treated as though immediately vested on the Eligible Participant’s Separation Date.  All such (time-based) Company Equity Awards will be settled through the vesting and issuance or delivery of shares of Stock within sixty (60) days after the Eligible Participant’s Separation Date, subject to an effective Separation Agreement and Release.
(b)Performance-Based Awards.  If a Change in Control occurs during the performance period applicable to a Company Equity Award that vests based on the achievement of performance targets over a given performance period, (i) other than the CEO PSU Award, and (ii) any AIP Shares, then such Company Equity Award will be subject to Section 11.2 of the Equity Award Incentive Plan.  In the event the Eligible Participant’s Separation Date occurs within the Change in Control Period and (i) on or following the consummation of the Change in Control, then such Company Equity Awards will be treated as though immediately vested on the Eligible Participant’s Separation Date, or (ii) prior to the consummation of the Change in Control, then such Company Equity Awards will be treated as though immediately vested on the consummation of the Change in Control.  All such (performance-based) Company Equity Awards will be settled through the vesting and issuance or delivery of shares of Stock within sixty (60) days after the applicable vesting date, subject to an effective Separation Agreement and Release.
(c)CEO PSU Award.  If a Change in Control occurs during the performance period of the CEO PSU Award, then such CEO PSU Award will be subject to the terms and conditions of the CEO PSU Award agreement.

	Outplacement	Pursuant and subject to the terms and conditions of the Plan, the Eligible Participant will be eligible for transition program services.

18

Executive Vice President
						
	Outside of a Change in Control Period
	Qualifying Termination	“Qualifying Termination” will mean:
(a)involuntary termination by the Company for a reason other than Cause or Disability;
(b)resignation by the Eligible Participant due to Good Reason; or
(c)solely for purposes of the treatment of Company Equity Awards, death or Disability.
“Good Reason” will mean: 
(a)a material reduction in the Eligible Participant’s annual base salary; 
(b)a material reduction in the Eligible Participant’s annual target bonus opportunity; 
(c)a material reduction in the Eligible Participant’s authority, duties or responsibilities (which would include a failure to report to the Chief Executive Officer); or 
(d)any material breach by the Company of the offer letter agreement between the Company and the Eligible Participant, as amended from time to time; in each case without such Eligible Participant’s written consent and subject to the notice and cure conditions set forth in the Plan.

	Severance Pay Benefit	Severance Pay Benefit will mean:
(a)1.5 times the sum of the Eligible Participant’s (i) annual rate of base salary immediately prior to the Separation Date (without regard to any reduction by the Company that gives rise to Good Reason) and (ii) target AIP bonus amount for the year in which the Separation Date occurs; and 
(b)Prorated AIP bonus amount for the year in which the Separation Date occurs, based on the number of full months Eligible Participant was employed with the Company during the AIP performance period and the actual Company performance through the end of the AIP performance period and target level of individual performance, settled in the form provided for under the terms and conditions of the relevant AIP, including without limitation, AIP Shares, as defined in the relevant AIP, if applicable.

	Health Benefits	Pursuant and subject to the terms and conditions of the Plan, the Eligible Participant will be eligible for the reimbursement of COBRA health premiums or payment of health premiums, at COBRA rates, for 12 months after the Separation Date or, if shorter, until the Eligible Participant becomes covered under a group health plan maintained by a subsequent employer, or other health plans, such as Medicare.

						
	Company Equity Awards	Pursuant and subject to the terms and conditions of the Plan, the Eligible Participant will be eligible for the following Company Equity Award severance benefits:
(a)Time-Based Awards.  All Company Equity Awards that are unvested as of the date prior to the Eligible Participant’s Separation Date and vest solely based on the continued service of the Eligible Participant (i.e., time-vesting awards), will be treated as though immediately vested on the Eligible Participant’s Separation Date as to the portion of such Company Equity Awards that would have otherwise become vested pursuant to their regular vesting schedule prior to the 12-month anniversary of the Separation Date (or, in the case of a termination due to Disability, any Company Equity Awards granted to the Eligible Participant prior to July 1, 2021 that would have otherwise become vested pursuant to their regular vesting schedule prior to the 24-month anniversary of the Separation Date will be treated as though immediately vested on the Eligible Participant’s Separation Date and Company Equity Awards granted to the Eligible Participant on or after July 1, 2021 shall be eligible for continued vesting in accordance with Appendix B).  Any such Company Equity Awards granted to the Eligible Participant prior to July 1, 2021 will be settled through the vesting and issuance or delivery of shares of Stock within sixty (60) days after the Eligible Participant’s Separation Date and any such Company Equity Awards granted to the Eligible Participant on or after July 1, 2021 will be eligible to continue vesting in accordance with their original vesting schedule following the Eligible Participant’s Separation Date, in each case subject to an effective Separation Agreement (including the Release/Certification Requirements set forth in Appendix B) and Release; provided that to the extent such Company Equity Award is scheduled to vest more frequently than annually, any continued vesting date not falling on an anniversary of the grant date of such Company Equity Award shall be deemed to fall on the next following anniversary of such grant date.  
(b)Performance-Based Awards.  All Company Equity Awards that are unvested as of the date prior to the Eligible Participant’s Separation Date and vest based on the achievement of performance targets over a given performance period, other than any AIP Shares, will remain outstanding and eligible to vest, based solely on the achievement of the applicable Company performance targets for any performance period that ends prior to the 12-month anniversary of the Separation Date; and, following the end of the performance period, the Company will determine the number of shares subject to such Company Equity Awards earned based on actual Company achievement of the performance goals pursuant to the terms of the applicable award agreements, and such Company Equity Awards will be settled in accordance with the terms and conditions of the applicable award agreement on the date that similar awards held by other participants are settled; provided, that in the case of a termination due to Disability, such Company Equity Awards granted to the Eligible Participant prior to July 1, 2021 will become immediately vested, based on target achievement of the performance targets, on the Eligible Participant’s Separation Date to the extent they are subject to a performance 

20

						
		period that ends prior to the 24-month anniversary of the Separation Date and Company Equity Awards granted to the Eligible Participant on or after July 1, 2021 shall be eligible for continued vesting in accordance with Appendix B. All such Company Equity Awards will be settled through the vesting and issuance or delivery of shares of Stock within sixty (60) days after the applicable vesting date, subject to an effective Separation Agreement (including the Release/Certification Requirements set forth in Appendix B) and Release.

For the avoidance of doubt, any continued vesting of Company Equity Awards pursuant to this section, other than Company Equity Awards that were outstanding prior to July 1, 2021 to the extent they were eligible for accelerated or continued vesting in accordance with this section as in effect prior to July 1, 2021, shall be subject to the Eligible Participant satisfying the Release/Certification Requirements set forth in Appendix B.

	Outplacement	Pursuant and subject to the terms and conditions of the Plan, the Eligible Participant will be eligible for transition program services.

21

Executive Vice President
						
	Within a Change in Control Period
	Qualifying Termination	“Qualifying Termination” will mean:
(a)involuntary termination by the Company for a reason other than Cause or Disability;
(b)resignation by the Eligible Participant due to Good Reason; or
(c)solely for purposes of the treatment of Company Equity Awards, death or Disability.
“Good Reason” will mean: 
(a)a material reduction in the Eligible Participant’s annual base salary; 
(b)a material reduction in the Eligible Participant’s annual target bonus opportunity; 
(c)a material reduction in the Eligible Participant’s authority, duties or responsibilities (which would include a failure to report to the Chief Executive Officer); 
(d)a requirement by the Company that the Eligible Participant relocate his or her primary office to a location that is more than 35 miles from the location of his or her primary office immediately prior to the Change in Control; or
(e)any material breach by the Company of the offer letter agreement between the Company and the Eligible Participant, as amended from time to time; in each case without such Eligible Participant’s written consent and subject to the notice and cure conditions set forth in the Plan.

	Severance Pay Benefit	Severance Pay Benefit will mean:
(a)Two times the sum of the Eligible Participant’s (i) annual rate of base salary immediately prior to the Separation Date (without regard to any reduction by the Company that gives rise to Good Reason) and (ii) target AIP bonus amount for the year in which the Separation Date occurs; and
(b)Prorated AIP bonus amount for the year in which the Separation Date occurs, based on the number of full months Eligible Participant was employed with the Company during the AIP performance period and the actual Company performance through the end of the AIP performance period and target level of individual performance, settled in the form provided for under the terms and conditions of the relevant AIP, including without limitation, AIP Shares, as defined in the relevant AIP, if applicable.

	Health Benefits	Pursuant and subject to the terms and conditions of the Plan, the Eligible Participant will be eligible for a lump sum payment of 24 months of health premiums, at COBRA rates, to be paid within sixty (60) days following the Separation Date.

						
	Company Equity Awards	Pursuant and subject to the terms and conditions of the Plan, the Eligible Participant will be eligible for the following Company Equity Award severance benefits:
(a)Time-Based Awards.  All Company Equity Awards that are unvested as of the date prior to the Eligible Participant’s Separation Date and vest solely based on the continued service of the Eligible Participant (i.e., time-vesting awards), will be treated as though immediately vested on the Eligible Participant’s Separation Date.  All such Company Equity Awards will be settled through the vesting and issuance or delivery of shares of Stock within sixty (60) days after the Eligible Participant’s Separation Date, subject to an effective Separation Agreement and Release.
(b)Performance-Based Awards.  If a Change in Control occurs during the performance period applicable to a Company Equity Award that vests based on the achievement of performance targets over a given performance period, other than any AIP Shares, then such Company Equity Award will be subject to Section 11.2 of the Equity Award Incentive Plan.  In the event the Eligible Participant’s Separation Date occurs within the Change in Control Period and (i) on or following the consummation of the Change in Control, then such Company Equity Awards will be treated as though immediately vested on the Eligible Participant’s Separation Date, or (ii) prior to the consummation of the Change in Control, then such Company Equity Awards will be treated as though immediately vested on the consummation of the Change in Control.  All such Company Equity Awards will be settled through the vesting and issuance or delivery of shares of Stock within sixty (60) days after the applicable vesting date, subject to an effective Separation Agreement and Release.

	Outplacement	Pursuant and subject to the terms and conditions of the Plan, the Eligible Participant will be eligible for transition program services.

23

APPENDIX B 
EXECUTIVE LONG TERM INCENTIVE PROGRAM
Under the Plan, Eligible Participants are entitled to the benefits set forth in this Appendix B, based on their employment classification as of the date of termination, which will be paid or provided in accordance with the terms and conditions of the Plan to which this Appendix B is attached. The definitions of capitalized terms defined in this Appendix B apply to Appendix B only. 

Executive Long Term Incentive Program 
						
	
	Qualifying Termination	For purposes of the Executive Long Term Incentive Program (the “ELTIP”) only:

“Qualifying Termination” will mean:
(a)     Qualifying Retirement (as defined below); or
(b)     Job Elimination (as defined below); or
(c)      death or Disability.
“Qualifying Retirement” will mean a voluntary resignation by an Eligible Participant from the Company and its subsidiaries which satisfies each of the following requirements:
(a)     The Eligible Participant provides sufficient advance notice to the Company, as determined solely by the Plan Administrator, which shall be no less than 12 months; 
(b)     The resignation is upon terms and conditions mutually agreed to by the Company and the Eligible Participant; 
(c)     The Eligible Participant provides a minimum of seven (7) years of continuous service to the Company as a Vice President or a higher position of the Company as of the day of such Eligible Participant’s voluntary resignation; and
(d)     The Eligible Participant is sixty (60) years of age or older.
For purposes of a Qualifying Retirement only, the effective date for which an Eligible Participant may become entitled to benefits is based on the Eligible Participant’s employment classification as follows: 

Job Classification     Effective Date
CEO or EVP     July 1, 2021
SVP     July 1, 2022
VP     July 1, 2023

“Job Elimination” will mean an involuntary termination by the Company due to a job elimination or role restructuring, as determined in the sole discretion of the Chief Executive Officer, Chief Human Resources Officer or the Chief Legal Officer of the Company (or their respective successors).   

In order for any termination to be a Qualifying Termination for purposes of the ELTIP (other than death), the Eligible Participant must (i) provide services as requested by the Company in a cooperative and professional manner following notification of employment termination, and (ii) satisfy the Release/Certification Requirements set forth below.

						
	Release/Certification Requirements	To qualify for continued vesting after termination of employment under any of the circumstances as set forth in this ELTIP, the Eligible Participant must satisfy each of the following requirements:
•the Eligible Participant must timely execute and deliver a release of claims in favor of the Company, in the form and within the period specified by the Plan Administrator or its delegate;
•with respect to a Qualifying Retirement, prior to the termination of employment, the Eligible Participant must provide written confirmation to the Company that he or she meets the eligibility criteria and receive written consent from the Company for such continued vesting;
•while the employment restrictions (see “Restrictions” below) are outstanding, the Eligible Participant must certify in the form specified by the Plan Administrator, prior to each vesting date, that the Eligible Participant complies with the employment restrictions from the date of termination of employment through the applicable vesting date;
•with respect to Disability, such Eligible Participant must satisfy the requirements described above and receive written consent from the Company for such continued vesting; and
•in all cases, complies with all other terms of this ELTIP, including each of the restrictions identified below.

	Restrictions	The Eligible Participant is subject to continued certification of his or her compliance with all of the following restrictions in the form specified by the Plan Administrator.   Subject to all of the other terms and conditions set forth in this Plan, the benefits provided under this Plan shall become vested and payable to an Eligible Participant only if the Eligible Participant satisfies each of the following vesting conditions, as determined by the Plan Administrator in good faith.

Confidentiality
The Eligible Participant must comply with the confidentiality provisions set forth in the Company’s Proprietary Information and Inventions Agreement (the “PIIA”) during and following his or her employment with the Company.

Non-Solicitation of Employees and Customers
During the Eligible Participant’s employment by the Company and for the longer of (i) the one-year period following his or her termination of employment, or (ii) during any remaining vesting periods of any equity awards held if he or she continues to vest after termination of employment with the Company, the Eligible Participant will not directly or indirectly, whether on his or her own behalf or on behalf of any other party, without the prior written consent of the EVP, Chief Business Affairs and Legal Officer (or its successor):  (a) solicit, induce or encourage any of the Company’s then current employees to leave the Company or to apply for employment elsewhere; or (b) solicit or induce or attempt to induce to leave the Company, or divert or attempt to divert from doing business with the Company, any then current customers, suppliers or other persons or entities that were serviced by the Eligible Participant or whose names became known to the Eligible Participant by the virtue of his or her employment with the Company or otherwise interfere with the relationship between the Company and such customers, suppliers or other persons or entities. 

26

						
		These restrictions do not apply to authorized actions the Eligible Participant took in the normal course of his or her employment with the Company, such as employment decisions with respect to employees the Eligible Participant supervised or business referrals in accordance with the Company’s policies. 

Non-Competition
During the Eligible Participant’s employment by the Company and for the longer of (i) the one-year period following the termination of his or her employment or (ii) during any remaining vesting periods of any equity awards held if the Eligible Participant continues to vest after termination of employment with the Company, the Eligible Participant will not, (a) directly or indirectly, as an officer, director, employee, consultant, owner, partner, or in any other capacity solicit, perform, or provide, or attempt to perform or provide Conflicting Services (as defined below) anywhere in the Restricted Territory (as defined below), nor will the Eligible Participant assist another person to solicit, perform or provide or attempt to perform or provide Conflicting Services anywhere in the Restricted Territory or (b) work in the Eligible Participant’s profession; provided that the Eligible Participant may work for a government, education or Not-for-Profit Organization (as defined below) and provide board of director services, in each case not deemed to be Conflicting Services; and provided further that in the event that the Eligible Participant seeks to work for an organization to exclusively provide services to a government, education or Not-for-Profit Organization, in each case not deemed to be Conflicting Services, the Eligible Participant must seek consent from the Company, which consent may be withheld in the Company’s sole discretion.

“Restricted Territory” means the 50 mile radius of any of the following locations: (i) any Company business location at which the Eligible Participant has worked on a regular or occasional basis during the preceding year; (ii) the Eligible Participant’s home if Eligible Participant worked from home on a regular or occasional basis; (iii) any potential business location of Company under active consideration by Company to which the Eligible Participant has traveled in connection with the consideration of that location; (iv) the primary business location of a Customer or Potential Customer; or (v) any business location of a Customer or Potential Customer where representatives of the Customer or Potential Customer with whom the Eligible Participant has been in contact in the preceding year are based.

“Customer or Potential Customer” is any person or entity who or which, at any time during the one year period prior to the Eligible Participant’s contact with such person or entity if such contact occurs during the Eligible Participant’s employment or, if such contact occurs following the termination of my employment, during the one year period prior to the date the Eligible Participant’s employment with the Company ends: (i) contracted for, was billed for, or received from the Company any product, service or process with which the Eligible Participant worked directly or indirectly during employment by the Company or about which the Eligible Participant acquired Proprietary Information (as defined in the PIIA); or (ii) was in contact with the Eligible Participant or in contact with any other employee, owner, or agent of the Company, of which contact the Eligible Participant was or should have been aware, concerning the sale or purchase of, or contract for, any product, service or process with which the Eligible Participant worked directly or indirectly during the Eligible Participant’s employment with the Company or about which the Eligible Participant acquired Proprietary Information (as defined in the 

27

						
		PIIA); or (iii) was solicited by the Company in an effort in which the Eligible Participant involved or of which the Eligible Participant was aware.

“Conflicting Services” means any product, service, or process or the research and development thereof, of any person or organization other than the Company that directly competes with a product, service, or process, including the research and development thereof, of the Company with which the Eligible Participant worked directly or indirectly during employment by the Company or about which the Eligible Participant acquired Proprietary Information (as defined in the PIIA) during the Eligible Participant’s employment by the Company.  
“Not-for-Profit Organization” means an entity exempt from tax under state law and under Section 501(c)(3) of the Code. Section 501(c)(3) only includes entities organized and operated exclusively for religious, charitable, scientific, testing for public safety, literary or educational purposes, or to foster national or international amateur sports competition or for the prevention of cruelty to children or animals. Not-for-Profit Organization shall also mean entities outside the United States exempt from local and national tax laws because they are organized and operated exclusively for purposes identical to those applicable to Section 501(c)(3) organization.
Nondisparagement
The Eligible Participant must not utter or publish (including, but not limited to, written, oral, or website, social media or similar internet-based publication) any disparaging, derogatory or negative statements, comments, or remarks concerning the Company, or the Company’s officers, directors, employees, shareholders and agents, affiliates and subsidiaries in any manner likely to be harmful to them or their business, business reputation or personal reputation; provided, that the Eligible Participant will respond accurately and fully to any question, inquiry or request for information when required by legal process.  
Cooperation
The Eligible Participant must cooperate fully with the Company and its counsel, upon request, with respect to any potential or pending proceeding (including, but not limited to, any litigation, arbitration, regulatory proceeding, investigation or governmental action) that relates at least in part to matters with which the Eligible Participant was involved while he or she was an employee or other service provider of the Company or any of its affiliates, or with which the Eligible Participant has knowledge.  The Eligible Participant must render such cooperation in a timely fashion and provide Company personnel and counsel with the full benefit of the Eligible Participant’s knowledge with respect to any such matter, and must be reasonably available for interviews, depositions, or court appearances at the request of the Company or its counsel.  If the Eligible Participant receives a complaint or subpoena or other legal process relating to the Company or a request for interview or to provide information concerning any existing, potential or threatened claims against the Company, the Eligible Participant must give written notice to the Company within seven days of receipt and prior to the Eligible Participant’s response to any such process or communication, unless prohibited by applicable law.  The Eligible Participant must cooperate with the

28

						
		Company in good faith to ensure that its trade secrets and other confidential and proprietary information are not disclosed, either intentionally or inadvertently.

	Company Equity Awards	If the Eligible Participant has a Qualifying Termination, and pursuant and subject to the terms and conditions of the Plan, the Eligible Participant will be eligible for the following Company Equity Award benefits:

(a)Time-Based Awards.  All Company Equity Awards that are unvested as of the date prior to the Eligible Participant’s Separation Date and vest solely based on the continued service of the Eligible Participant (i.e., time-vesting awards), after taking into account any accelerated vesting of outstanding time-based equity awards as of July 1, 2021 in connection with the Eligible Participant’s Separation from Service (as provided for in Appendix A or C or other Company policies, as applicable), will be eligible to continue vesting  in accordance with their original vesting schedule; provided that to the extent a Company Equity Award is scheduled to vest more frequently than annually, any continued vesting date not falling on an anniversary of the grant date of such Company Equity Award shall be deemed to fall on the next following anniversary of such grant date, until the Company Equity Award is completely vested. 

Notwithstanding the above, in the event that the Eligible Participant terminates service for reason of Qualifying Retirement, and the Eligible Participant has outstanding time-based equity awards as of July 1, 2021, then those outstanding awards will be eligible for pro-rata acceleration in addition to the continued vesting set forth in the paragraph above. The pro-rata acceleration will be determined for each such award as follows: (i) the product of (A) the aggregate number of shares of stock underlying the award, multiplied by (B) the Eligible Participant’s number of full months of service since the date of grant, divided by the total number of months of vesting to which the award is subject (e.g., thirty-six months if the vesting schedule of the award is three years), minus (ii) any shares issued on previous vesting dates of the award.  The result shall be rounded up to the nearest whole share of stock. Any remaining shares after the pro-rata acceleration is applied will not be forfeited and will continue to vest on the original vesting date(s) in accordance with the ELTIP. 

(b)Performance-Based Awards.  All Company Equity Awards that are unvested as of the date prior to the Eligible Participant’s Separation Date and vest based on the achievement of performance targets over a given performance period, other than any AIP Shares, will remain outstanding and eligible to vest, based solely on the achievement of the applicable Company performance targets for the applicable performance period.  Following the end of each applicable performance period, the Company will determine the number of shares subject to such Company Equity Awards earned based on actual Company achievement of the performance goals pursuant to the terms of the applicable award agreements, and such Company Equity Awards will be settled in accordance with the terms and conditions of the applicable award agreement, on the date that similar awards held by other participants are settled.

29

						
		applicable award agreements, and such Company Equity Awards will be settled in accordance with the terms and conditions of the applicable award agreement, on the date that similar awards held by other participants are settled.

(c)    Notwithstanding the above, in the event of the Eligible Participant’s termination due to death, all Company Equity Awards that are eligible to continue vesting pursuant to the ELTIP will become immediately vested on the date of the Eligible Participant’s death. For Company Equity Awards that are performance-based awards, any such accelerated vesting will be based on target achievement of the applicable performance targets. All such Company Equity Awards will be settled through the vesting and issuance or delivery of shares of Stock within sixty (60) days after the applicable vesting date, subject to an effective Separation Agreement and Release.

For the avoidance of doubt, any continued vesting of Company Equity Awards pursuant to the ELTIP, other than Company Equity Awards that were outstanding prior to July 1, 2021 to the extent they were eligible for accelerated or continued vesting in accordance with the applicable appendix as in effect prior to July 1, 2021, shall be subject to the Eligible Participant satisfying the Release/Certification Requirements set forth herein.

For the avoidance of doubt, the ELTIP (including any continued or accelerated vesting benefits provided under the ELTIP) shall not apply to the performance-based Company Equity Award that was granted on April 1, 2018 to the CEO, which award shall be subject to the applicable terms and conditions set forth in the award agreement and Appendix A. 

	Health Benefits	Pursuant and subject to the terms and conditions of the Plan, the Eligible Participant will be eligible for Company-subsidized health care coverage or payments in lieu thereof at COBRA rates, to be determined at the Plan Administrator’s sole discretion, for the period during which the Eligible Participant is eligible to continue vesting in any Company Equity Awards pursuant to the ELTIP. Notwithstanding the foregoing, no Eligible Participant will be eligible for continued health care coverage under the Company’s group health plans, or payments in lieu thereof, to the extent that the Eligible Participant is no longer eligible for or participates in continuation coverage under COBRA.  If the Eligible Participant is eligible to continue vesting in any Company Equity Awards pursuant to the ELTIP and the Eligible Participant is no longer eligible for COBRA continuation coverage under the Company’s group health plans and is not covered under any other group health plan, the Eligible Participant will be eligible to receive prorated payments, calculated using COBRA rates, on the first vesting date of each year that unvested Company Equity Awards vest pursuant to the ELTIP.  Each prorated payment will be determined by multiplying the monthly COBRA rate at the time the Eligible Participant is no longer covered under COBRA by a fraction, the numerator of which is the number of full months between the later of the COBRA coverage end date and the most recent Company Equity Award vesting date and the denominator of which is the number of full months between the COBRA coverage end date and the last vesting date under the ELTIP.

30

						
		For the avoidance of doubt, no benefits shall be provided pursuant to this section to the extent that they would result in a duplication of benefits, as determined by the Plan Administrator.

31

PayPal Holdings, Inc.
Executive Change in Control and Severance Plan
Form Letter Agreement for Executives with Individual Separation Protection Agreements

Employee Name
Employee Address
 
									
	 	Re:	The PayPal Holdings, Inc. Executive Change in Control and Severance Plan

Dear [Employee Name]:
This letter agreement (“Letter Agreement”) relates to the PayPal Holdings, Inc. Executive Change in Control and Severance Plan (the “Plan”).
Through this Letter Agreement, you are being offered the opportunity to become a participant in the Plan (a “Participant”), and thereby to be eligible to receive the severance benefits set forth therein. A copy of the Plan is attached to this Letter Agreement. You should read it carefully and become comfortable with its terms and conditions, and those set forth below.
By signing below, you will be acknowledging and agreeing to the following provisions:
 
									
	 	(a)	that you have received and reviewed a copy of the Plan;

									
	 	(b)	that capitalized terms not defined in this Letter Agreement will have the meaning assigned to them in the Plan;

									
	 	(c)	that participation in the Plan requires that you agree irrevocably and voluntarily to the terms of the Plan and the terms set forth below; and

									
	 	(d)	that you have had the opportunity to carefully evaluate this opportunity, and desire to participate in the Plan according to the terms and conditions set forth herein.

Subject to the foregoing, we invite you to become a Participant in the Plan. Your participation in the Plan will be effective upon your signing and returning this Letter Agreement to the Company.
NOW, THEREFORE, you and the Company (hereinafter referred to as “the parties”) hereby AGREE as follows:
1.The Company and you have previously entered into that certain offer letter dated as of [ • ] and as thereafter supplemented and amended from time to time (the “Employment Agreement”). 

2.If you incur a Qualifying Termination, you will receive the Severance Benefits set forth in Section 5 of the Plan (the “Severance Benefits”).

3.As a condition of receiving the Severance Benefits (other than any Accrued Amounts), you must (i) execute and accept the terms and conditions of, and the effectiveness of, a Separation Agreement and Release and such Release must become irrevocable within sixty (60) days following your Separation Date, (ii) comply with the terms and conditions of the Plan and (iii) promptly resign from any position as an officer, director or fiduciary of the Company or any Company-related entity.

4.In consideration of becoming eligible to receive the Severance Benefits provided under the terms and conditions of the Plan, you agree to waive any and all rights, benefits, and privileges to severance benefits that you might otherwise be entitled to receive under the Employment Agreement or any other plan or arrangement. 

5.You understand that the waiver set forth in Section 4 above is irrevocable for so long as this Letter Agreement is in effect, and that this Letter Agreement and the Plan set forth the entire agreement between the parties with respect to any subject matter covered herein.

6.Notwithstanding anything herein to the contrary, if a Change in Control occurs while you are a Participant in the Plan, in no event will your status as a Participant in the Plan end prior to the end of the twenty-four (24) month period beginning on a Change in Control regardless of when any written notification is given to you terminating your participation in the Plan (including any written notification given prior to such Change in Control).

7.Your participation in the Plan will continue in effect following any Qualified Termination that occurs while you are a Participant in the Plan with respect to all rights and obligations accruing as a result of such termination.

8.You recognize and agree that your execution of this Letter Agreement results in your enrollment and participation in the Plan, that you agree to be bound by the terms and conditions of the Plan and this Letter Agreement, and that you understand that this Letter Agreement may not be terminated, modified or amended in any manner that is adverse to you, without your consent.
 
																								
								
		 	 	PayPal Holdings, Inc.
		 	 	
					
		 		 	 	By	 	 

ACCEPTED AND AGREED TO this      day of ___________, ________.
 
			
	
	
	  
	Your Name (printed)
	
	  
	Your Signature

 
33

PayPal Holdings, Inc.
Executive Change in Control and Severance Plan
Form Consent for Executives with Previous Individual Separation Protection Agreements

Employee Name
Employee Address
 
									
	 	Re:	Amendment to PayPal Holdings, Inc. Executive Change in Control and Severance Plan

Dear [Employee Name]:
This letter agreement (“Letter Agreement”) relates to the PayPal Holdings, Inc. Executive Change in Control and Severance Plan (the “Plan”).
PayPal Holdings, Inc. (the “Company”) amended the Plan, effective as of July 1, 2021. A copy of the Plan, as amended and restated, is attached to this Letter Agreement. You should read it carefully and become comfortable with its terms and conditions.
By signing below, you acknowledge and agree that:
 
									
	 	(a)	you have received and reviewed a copy of the Plan, as amended and restated; and

									
	 	(b)	you affirmatively consent to the Plan, as amended and restated.

 

 
																								
								
		 	 	PayPal Holdings, Inc.
		 	 	
					
		 		 	 	By	 	 

ACCEPTED AND AGREED TO this      day of ___________, ________.
 
			
	
	
	  
	Your Name (printed)
	
	  
	Your SignatureExhibit 10.1

 

[Certain identified information has been excluded
from the exhibit because it is both (i) not material and (ii) would be competitively harmful if disclosed.]

 

EXCLUSIVE LICENSE AND DISTRIBUTION AGREEMENT

 

This Exclusive License and Distribution Agreement
is made and entered into as of November 9, 2021 (hereinafter the “Effective Date”) by and between:

 

Sonoma Pharmaceuticals, Inc., a company
incorporated and existing under the laws of Delaware, USA, having its principal office at 645 Molly Lane, Suite 150, Woodstock, Georgia,
30189, United States of America,

 

hereinafter referred to as «SONOMA»,
on the one hand

 

and

 

Dyamed Biotech Pte Ltd., a private corporation
duly incorporated and existing under the laws of the Republic of Singapore, with its principal office at 10 Ubi Crescent, Lobby C, #02-41
Ubi Techpark, Singapore, 408564, Singapore,

 

hereinafter referred to as «DYAMED»,
on the other hand.

 

SONOMA and DYAMED are herein individually referred
to as a “Party” and collectively referred to as “Parties”.

 

		WHEREAS:	

 

		A.	SONOMA, through its wholly-owned subsidiary, Oculus Technologies of Mexico, S.A. de C.V., manufactures
the product described in Schedule 1 hereto (hereinafter referred to as the “Product”) and currently holds all rights to the
Product, including in particular in the Territory.

 

		B.	SONOMA currently markets the Product internationally and has obtained marketing authorizations for the
Product in various countries.

 

		C.	DYAMED and SONOMA have previously entered into an Exclusive Distributorship Agreement dated October 20,
2005;

 

		D.	DYAMED wishes that SONOMA grant to DYAMED the exclusive right to purchase, import, distribute, sell and
promote the Products in the Territory;

 

		E.	DYAMED wishes that SONOMA grant to DYAMED an exclusive license to use the SONOMA’s Trademarks filed
or registered in the Territory with respect to the Product.

 

Now, therefore, in consideration of the above
and the mutual promises set forth below, SONOMA and DYAMED agree as follows:

 

		1.	INTERPRETATION AND DEFINITIONS

 

		1.1	For the purposes of this Agreement or any notice, consent, authorization, direction or other communication
required or permitted to be given hereunder, the singular shall include the plural and vice versa and the following expressions shall
have the following meanings, respectively, unless the context otherwise requires:

 

 

    	 	1	 

     

    

 

		(i)	“Affiliate” means a company that, directly or indirectly, through one or more intermediaries,
controls, is controlled by, or is under common control with the company specified. For the purposes of this definition, control will mean
the direct or indirect ownership of (a) in the case of corporate entities, securities authorized to cast more than fifty percent (50%)
of the votes in any election of directors, (b) in the case of non-corporate entities, more than fifty percent (50%) ownership interest
with the power to direct the management and policies of such non-corporate entity.

 

		(ii)	“Business Day” means any day except Saturday, Sunday and statutory holidays, on which
commercial banking institutions in Petaluma/CA, USA and Singapore are open for business. Any reference in this Agreement to “day”
whether or not capitalized will refer to a calendar day, not a Business Day.

 

		(iii)	“Commercially Reasonable Efforts” means, with respect to the efforts to be expended
by a Party in the performance of such Party’s obligations hereunder, the reasonable, diligent efforts to accomplish such objective
as a similarly situated party in the pharmaceutical industry would normally use to accomplish a similar objective under similar license
grants and circumstances.

 

		(iv)	“Confidential Information” means all secret, confidential or proprietary information
or data, whether provided in written, oral, graphic, video, digital or other form, provided by one Party (the “Disclosing Party”)
to the other Party (the “Receiving Party”) pursuant to this Agreement or generated pursuant to this Agreement, including but
not limited to, information relating to the Disclosing Party’s existing or proposed research, development efforts, patent applications,
promotional materials, ideas, strategies, clinical trials, quotations, development lists, formulae, manufacture processes, concepts, businesses
plans, marketing data, scientific data, prototypes, samples, scientific and technical information, projects, processes, procedures, know-how,
products, the terms of this Agreement and any other materials that have not been made available by the Disclosing Party to the general
public, including all information disclosed during the negotiations preceding this Agreement. Notwithstanding the foregoing, Confidential
Information will not include any information or materials that:

 

		(a)	were already known to the Receiving Party (other than under an obligation of confidentiality), at the
time of disclosure by the Disclosing Party to the extent such Receiving Party has documentary evidence to that effect;

 

		(b)	were generally available to the public at the time of its disclosure to the Receiving Party;

 

		(c)	became generally available to the public or otherwise part of the public domain after its disclosure or
development, as the case may be, and other than through any act or omission of a Party in breach of the confidentiality obligations under
this Agreement;

 

		(d)	were subsequently lawfully disclosed to the Receiving Party by a Third Party who had no obligation not
to disclose such information to others;

 

		(e)	were independently discovered or developed by or on behalf of the Receiving Party without the use of the
Confidential Information belonging to the other Party and the Receiving Party has documentary evidence to that effect; or

 

	 	(f)	is approved for disclosure by the Disclosing Party in writing.

 

Information included in the Confidential
Information shall not be deemed to be in the public domain or in the possession of either Party merely because the information is embraced
by partial or generalized disclosures in the public domain, nor will a combination of information be deemed to fall within any of the
exceptions set forth above simply because each of the elements is itself included within an exception if the significance of the combination
does not fall within any of the exceptions;

 

 

    	 	2	 

     

    

 

		(v)	“Contract Year “means each consecutive 12 (twelve) months period during the term of
this Agreement commencing on the Effective Date.

 

		(vi)	“Distribute”, “Distributed” or “Distribution”
means the import, storage, handling, transportation, sale, and offer for sale of Product.

 

		(vii)	“DYAMED Trademarks” means a trademark owned by DYAMED and used or required to be used
on the Packaging Materials and Marketing purposes for the Product pursuant this Agreement, applicable laws, and shall include, without
limitation, Ezyma and  Scarless, as listed in Schedule 2.

 

		(viii)	“Facility” means the Oculus Technologies of Mexico S.A. de C.V. facility in Industria
Vidriera 81, Fraccionamiento Industrial Zapopan Norte, Zapopan, Jalisco, Mexico or any future manufacturing facility that SONOMA may establish.

 

		(ix)	“Field” means human dermatology, oral and eye care.

 

		(x)	“Force Majeure Event” means any occurrence beyond the reasonable control of a Party
that prevents or substantially interferes with the performance by the Party of any of its obligations hereunder (other than payment obligations),
if such occurs by reason of any act of God, epidemics, pandemics, flood, fire, explosion, earthquake, strikes, out of the reasonable control
of the affected Party, casualty or accident; or war, revolution, civil commotion, acts of public enemies, terrorist attack, blockage or
embargo; or any injunction, law, order, proclamation, regulation, ordinance, demand or requirement of any government (to the extent such
government has ruling authority over such Party) or of any subdivision, authority or representative of any such government; or other similar
event, beyond the reasonable control of such Party.

 

		(xi)	“Governmental Authority” means any court, tribunal, arbitrator, agency, legislative
body, commission, department, bureau, official or other entity of (a) any government of any country, (b) a federal, state, province, region,
local, county, city or other political subdivision thereof, (c) any governmental or regulatory authority responsible for the grant of
Regulatory Approval including, or (d) any supranational body, in each case exercising governmental powers and having jurisdiction in connection
with this Agreement and action to be taken hereunder.

 

		(xii)	“Intellectual Property” shall mean any and all licenses, Know-How, rights to inventions
(whether or not reduced to writing), patents (including patents of addition, substitutions, reissues, extensions, reexaminations, renewals,
supplemental patent certificates, confirmation patents and registration patents), patent applications (including any provisionals, divisionals,
continuations, continuations-in-part and substitutions thereof), designs, design applications and design registrations, trademarks, trademark
applications, trademark registrations, trade names, trade dress, service marks, logos (whether registered or unregistered), copyrights,
copyright applications, copyright registrations, and other intellectual property rights now or hereafter recognized anywhere in the world
now or hereafter owned, held, prepared for or used by any of the Parties or any of its Affiliates.

 

		(xiii)	“Know-How” shall mean any data, results, technology, business information and other
information of any type whatsoever, in any tangible or intangible form, including know-how, trade secrets, practices, techniques, methods,
processes, inventions, developments, specifications, formulations, formulae, materials or compositions of matter of any type or kind (patentable
or otherwise), software, algorithms, marketing reports, expertise, technology, test data (including pharmacological, biological, chemical,
biochemical, toxicological, research, preclinical and clinical test data (including original patient report forms, investigator reports,
clinical protocols, statistical analyses, expert opinions and reports)), manufacturing data (including, analytical and quality control
data, stability data, other study data and procedures and other chemistry, manufacturing and control (CMC) data), safety or other adverse
reaction files and complaint files, presentations and papers from academic meetings or market research, in each case, together with all
supporting data and raw source data therefor, whether or not reduced to writing, now or hereafter owned by, in the possession of, known
to or controlled by any the Parties or its Affiliates;

 

 

    	 	3	 

     

    

 

		(xiv)	“Law” or “Laws” means the laws, statutes, rules, codes, regulations,
orders, judgments and/or ordinances of a Governmental Authority, and any implementing legislation or other applicable laws promulgated
by a Governmental Authority in the Territory, as any of the same may be amended from time-to-time, and directives, regulations, promulgations,
guidance and guidelines promulgated thereunder having jurisdiction over or related to the development, registration, approval, manufacture,
Marketing, Distribution and use of a Product in the Territory, as may be in effect from time-to-time.

 

		(xv)	“Market” or “Marketing” means activities directed to the marketing
or promotion of Finished Product, including appropriate mailings, attendance and participation at industry meetings and congresses, general
sales-force promotion, telesales, pre-marketing, advertising, educating and planning activities related to Finished Product. Marketing
will not include any activities related to research, manufacture or development of a Product.

 

		(xvi)	“Packaging Materials” means the label, package insert and carton for the outer packs
and all other packaging materials necessary for packaging Product.

 

		(xvii)	“Product” or “Products” means, collectively or individually as the
context requires, those SONOMA products specified in Schedule 1 of this Agreement.

 

		(xviii)	“Purchase Order” means each purchase order submitted by DYAMED to SONOMA pursuant to
Section 5.1(f) pursuant to which DYAMED orders Product from SONOMA.

 

		(xix)	“Regulatory Approval” or “Regulatory Approvals” means at the Effective
Date, all approvals (including, without limitation, where applicable, pricing approval), company and product registrations and renewals,
authorizations, permits, licenses, filings, and certifications of any Governmental Authority required to be held by a Party for the use,
Marketing and Distributing of a Product in the Territory, including without limitation, the Marketing Authorization.

 

		(xx)	“Sonoma Trademark” means a Trademark owned by SONOMA and used or required to be on
the Packaging Materials and Marketing purposes for the Product pursuant to this Agreement, applicable Laws, and shall include, without
limitation, Microcyn, as listed in Schedule 2.

 

		(xxi)	“Territory” means Indonesia, Malaysia, the Republic of Singapore and Thailand.

 

		(xxii)	“Third Party” means any person or company other than SONOMA, DYAMED or their respective
Affiliates.

 

	 	(xxiii)	“Trademark” means a trademark owned by a Party and any related word, name, symbol, color, shape or designation or
any combination thereof as well as any other word, name, symbol, color, shape or designation used in the performance by a Party of its
obligations hereunder or in the operation of its business, including any service mark, trade name, brand name, sub-brand name, trade
dress, product configuration, program name, delivery form name, certification mark, collective mark, logo, tagline, slogan, design or
business symbol, that functions as an identifier of source or origin, whether or not registered and all statutory and common law rights
therein and all registrations and applications therefor, together with all goodwill associated with, or symbolized by, any of the foregoing.

 

		1.2	The following are the Schedules annexed to and incorporated in this Agreement by reference and deemed
to be a part hereof:

 

Schedule
“1” - Products

 

Schedule
“2” - Trademarks

 

Schedule
“3” - Minimum Annual Purchase Amounts and Pricing

 

 

    	 	4	 

     

    

 

		2.	GRANT of RIGHTS

 

		2.1	Under the terms and conditions hereinafter set out, SONOMA hereby grants to DYAMED the exclusive right
during the term of this Agreement, subject to DYAMED meeting its Minimum Annual Purchase Amounts and payment of USD [_____] per Contract
Year for the first ten (10) Contract Years during the Term of this Agreement:

 

		(a)	to purchase the Product from SONOMA for import into the Territory at mutually agreed-upon prices;

 

		(b)	to use SONOMA’s Trademarks filed or registered in the Territory on a royalty-free basis, on the
Finished Product Packaging Materials and the promotional material produced by DYAMED and solely to Market, Distribute and sell the Finished
Product in the Territory for use in the Field, as defined in Section 2.4 herein.

 

		2.2	DYAMED may utilize its Affiliates and Third Party sub-distributors, subject to prior written approval
of SONOMA which shall not be unreasonably withheld, and provided that DYAMED remains liable for all the work, acts and omissions of its
Affiliates and sub-distributors, including compliance with the terms of this Agreement. No use of Affiliates or subcontractors will release
DYAMED from its responsibilities and liabilities under this Agreement including, but not limited to, its indemnification obligations.

 

		2.3	DYAMED shall not have the right to actively, and shall not actively, import, Market, sell, Distribute
or use, or authorize any Sub Distributor or Third Party to import, Market, sell, Distribute or use any Product outside of the Territory
or for any use outside of the Field, especially for sales through websites. If SONOMA or DYAMED become aware of Product sold outside of
the Territory, DYAMED will take prompt action to stop such sales. Ongoing sales outside of the Territory in any form, including online
sales, will be considered a breach of this Agreement

 

		2.4	SONOMA, as Licensor, grants to DYAMED, as Licensee, an exclusive, non-transferable license to use SONOMA’s
Trademarks in the Territory in connection with the Product and DYAMED accepts the license subject to the following terms and conditions.

 

		(a)	Sublicensing of the SONOMA’s Trademarks by DYAMED is only allowed upon the written approval by SONOMA
of the proposed sublicensee and the terms of any sublicense. Any sublicense will be subject to the terms of this Agreement, and SONOMA
has the right to terminate any sublicense that is in breach of those terms.

  

		(b)	DYAMED acknowledges the ownership of SONOMA’s Trademarks to SONOMA, agrees that it will do nothing
inconsistent with such ownership and that all use of SONOMA’s Trademarks by DYAMED shall inure to the benefit of and be on behalf
of SONOMA.

  

		(c)	DYAMED agrees it will not apply to register any of SONOMA’s Trademarks (or any other marks that
contain SONOMA’s Trademarks) in the Territory, or in any jurisdiction, during the term of this Agreement or thereafter.

  

		(d)	DYAMED agrees that nothing in this Agreement shall give DYAMED any right, title or interest in SONOMA’s
Trademarks other than the right to use SONOMA’s Trademarks in accordance with this Agreement and License.

  

		(e)	DYAMED agrees that it will not attack the title of SONOMA to SONOMA’s Trademarks.

  

		(f)	DYAMED agrees that the nature and quality of the Products provided by DYAMED under this Agreement, and
all related advertising, promotional, and other related uses of SONOMA’s Trademarks by DYAMED, shall conform to standards set by
SONOMA and will otherwise be under the control of SONOMA.

  

		(g)	DYAMED agrees to cooperate with SONOMA in facilitating SONOMA’s control of the nature and quality
of the Products and use of SONOMA’s Trademarks on the Products and all related advertising, promotional, and other related uses
of SONOMA’s Trademarks by DYAMED, and to permit reasonable inspection of DYAMED’s use of SONOMA’s Trademarks and the
Products, and to supply SONOMA with specimens of use of the SONOMA’s Trademarks by DYAMED on request.

  

 

    	 	5	 

     

    

 

		(h)	DYAMED shall comply with all applicable laws and regulations and obtain all appropriate government approvals
in the Territory pertaining to the sale of the Products covered by this Agreement.

  

		(i)	DYAMED agrees to use SONOMA’s Trademarks only in the form and manner as prescribed by SONOMA, which
may be changed from time to time with reasonable notice.

 

		3.	EXCLUSIVITY 

 

		3.1	SONOMA hereby appoints DYAMED, and DYAMED hereby accepts appointment, as SONOMA’s exclusive and
sole importer, handler, storer, seller, distributor and promoter of the Product solely for the purpose of Marketing, Distributing and
Selling the Product in the Territory for use in the Field as provided in this Agreement and shall grant to DYAMED an exclusive license
to use SONOMA’s Intellectual Property and Know How related to the Product solely to the extent required for DYAMED to Market the
Product in the Territory for use in the Field. DYAMED acknowledges and agrees that this Section does not grant to DYAMED any license or
rights, whether express or implied, to any trade secret owned by SONOMA. In addition, for the purposes of Marketing as provided in this
Section, DYMAMED shall only be entitled to use the Intellectual Properties and Know How disclosed by SONOMA for this purpose.

 

		3.2	DYAMED shall not have any right to and shall not import, export, Market, Distribute, obtain Regulatory
Approval or use any Product outside of the Territory or for any use outside the Field, or solicit any Third Party to maintain offices,
storage depots, etc. outside the Territory with the intention to Market, Distribute, import, export, sell or obtain Regulatory Approval
for a hypochlorous-based product; or (ii) to duplicate, reverse engineer, modify or adapt (A) Product, or (B) any documentation provided
by SONOMA, without SONOMA’s prior written consent.

 

		3.3	DYAMED warrants that: (i) it has and will maintain an adequate organization for the fulfilment of its
obligations under this Agreement; and (ii) it is an independent Party assuming the risks of its own activity and nothing contained herein
will be construed to create an agency, partnership, employment or joint venture relationship between SONOMA and DYAMED.

 

		4.	MINIMUM PURCHASE VOLUMES

 

		4.1	DYAMED shall purchase purchase a quantity of Products in each Contract Year equivalent to the amounts
in USD stated in Schedule 3 of this Agreement. Such amounts comprehend the entire portfolio of Products and do not refer to any specific
Product. As such, the Parties agree that DYAMED is not obligated to purchase any minimum amount of any individual Product.

 

		4.2	In the event that DYAMED fails to make purchases of Products at least equal to the Minimum Annual Purchase
Amount set forth in Schedule 3, DYAMED shall have up to [______] months to make Product purchases equal to the difference between the
Minimum Annual Purchase Amount for the applicable Contract Year and the amount actually received by SONOMA in such Contract Year (the
“Deficit Amount”), in which case the Deficit Amount shall be counted for the preceding Contract Year, and shall not be counted
for the then current Contract Year in which it is paid.

 

		4.3	If DYAMED fails to purchase the current Minimum Purchase Amount in the following Contract Year with the
addition of the Deficit Amount of the preceding Contract Year, SONOMA shall be entitled to cancel DYAMED’s exclusivity for the Products
in the Territory or to terminate the Agreement pursuant to Section 9.2(c). Revocation of exclusivity or termination, in whole (if the
noncompliance is in regard to all Products under this Agreement) or in part (if the noncompliance is in regard to one or more Products,
but not to all Products at such given moment, under this Agreement) of this Agreement shall be SONOMA’s exclusive remedy under this
Agreement.

 

 

    	 	6	 

     

    

 

		5.	TERMS OF IMPORTATION, PURCHASE AND SUPPLY

 

		5.1	During the term of this Agreement, DYAMED shall:

 

		(a)	Purchase its requirements of the Product from SONOMA at the prices set out in Schedule 3 hereto;

 

		(b)	At all times have suitable resources and shall hold all administrative permits to register, import, handle,
store, Market and Distribute the Product in the Territory. Costs for licenses and permits necessary to import, Market, Distribute the
Product as well as taxes, duties, levies and other charges in the Territory shall be borne by DYAMED;

 

		(c)	Provide SONOMA with a non-binding rolling forecast, broken down by month, of its estimated requirements
of Product for the next 15 (fifteen) months (the “Forecast”) within ten (10) days of the end of each Contract Year;

 

		(d)	Provide SONOMA with a Purchase Order for the Product specifying (i) the quantity of Products and (ii)
desired delivery date, which shall not be less than [_______] days prior to the desired delivery date. Each Purchase Order shall specify
such date and the quantities of the Product ordered. The Parties can agree a shorter delivery date for any single Purchase Order only
if SONOMA accepts such Purchase Order in writing, and, if so accepted by SONOMA, such delivery time will supersede the [_______] day
delivery time for such Purchase Order;

 

		(e)	Handle and store all Products in good condition and in compliance with the applicable Laws, regulations
and specific handling and storage instructions provided by SONOMA until their resale to customers;

 

		(f)	Using its best efforts to Market and Distribute the Product bearing the appropriate SONOMA Trademarks
that are required to be set forth on the Packaging Materials in compliance with applicable Laws in force in the Territory;

 

		(g)	Refrain, without SONOMA’s prior written consent, from (i) any modification to the delivered Product,
including the Packaging Material, or (ii) using or disposing of the Product for any purpose other than the purpose permitted hereunder
or by applicable Law, nor allowing a Sub Distributor or Third Party to modify the Product, Packaging Material or labeling;

 

		(h)	Monitor and control the stocks of the Product and comply with all applicable Laws as well as any specific
instructions for the Product. DYAMED bears the risk for expired Product delivered in accordance with the agreed shelf-life, as per Section
5.2(c); and

 

		(i)	Keep and maintain records of all sales and other distributions of Product made by DYAMED or its Sub Distributors
sufficient to effectively, efficiently, and economically implement any recall of any Product. Upon SONOMA’s request, DYAMED shall
make such records available to SONOMA and otherwise cooperate as reasonably required to implement any recall.

 

		5.2	During the term of this Agreement, SONOMA shall:

 

		(a)	Within [_____] business days from the receipt of each Purchase Order, accept in writing to DYAMED the
respective Purchase Order. If a Purchase Order exceeds the amount forecasted for the relevant month in the Forecast, SONOMA may accept
all or part of the amount ordered exceeds the Forecast amount. SONOMA shall not be entitled to reject any Purchase Order, as long as the
Purchase Order is consistent with the agreed Forecast and complies with Section 5.1(f) above. If SONOMA does not expressly accept or reject
the Purchase Order within the aforementioned period, the Purchase Order shall be deemed accepted as to the amount that is consistent with
the Forecast, and the delivery date shall be [_____] days from the date of receipt of such Order. Any variation to this commitment
will be managed by exception and agreed, in good faith, between the Parties. The quantities to be delivered by SONOMA shall not vary more
than [_____] percent from the quantities ordered or DYAMED shall be entitled to reject delivery, and all costs and expenses, including
taxes, duties and levies, for the return of the rejected quantities shall be borne by SONOMA;

 

 

    	 	7	 

     

    

 

		(b)	Tender the ordered Product to the forwarding agent appointed by DYAMED on the confirmed date of delivery
pursuant to paragraph 5.2(a) above. All shipment of Product shall be Ex-works, at the Facility located at Industria Vidriera 81, Fraccionamiento
Industrial Zapopan Norte, Zapopan, Jalisco, Mexico (INCOTERMS 2010) or any other manufacturing facility that SONOMA may establish.

 

		(c)	Warrant to DYAMED, any approved Sub Distributor and any original purchaser of Product from DYAMED pursuant
to the terms of this Agreement, that the Product sold to DYAMED under this Agreement shall, when delivered to DYAMED, meet the then effective
and agreed upon specifications and shall be free from defects in design, materials and workmanship. THIS WARRANTY SHALL BE EXCLUSIVE AND
IN LIEU OF ANY AND ALL OTHER WARRANTIES, EXPRESS OR IMPLIED (INCLUDING WITHOut limitation, any
implied warranty of merchantability or fitness). THE remedies set forth in this Agreement are exclusive and in lieu of any and all remedies
for any breach of SONOMa’s representations and warranties set forth in this paragraph;

 

		(d)	Replace at SONOMA’s own expense and as soon as possible after receipt of a written claim from DYAMED
which shall include such evidence or documentation reasonably appropriate:

 

		i.	subject to such claim being made within no more than 30 (thirty) days after delivery by SONOMA of the
Product in question as provided in Section 5.2(b) all quantities of the Product which are in shortage and/or present any visible defect
and/or fails to comply with the warranty set forth in paragraph 5.2(c).

 

		ii.	for all quantities of the Product with defects that are not in conformity with this Agreement that are
not readily discoverable within 30 (thirty) days (the “Latent Defects”) DYAMED shall promptly notify SONOMA of any Latent
Defects, but not later than 10 (ten) days after the date of discovery.

 

		iii.	should any dispute arise between the Parties in relation to the conformity of any batch of the Product
delivered to DYAMED, either Party shall be entitled to refer such batch to an independent expert who shall be appointed by mutual consent
of both Parties and whose decision, which shall be made within fifteen (15) days from the appointment, shall be binding and enforceable
upon both Parties, and the costs and fees of such expert and the transportation costs of the Product shall be borne by the Party whose
views shall not be upheld by the expert’s decision.

 

		(e)	Warrant to DYAMED that the Product does not infringe any Third Party rights whether it be by importing,
storing, selling, marketing or promoting the Product in the Territory;

 

		(g)	Be responsible for all packaging and labelling of Products.

 

		6	TERMS OF DISTRIBUTION of the PRODUCT

 

		6.1	DYAMED shall Market, distribute and sell the Product to customers for use in the Field in the Territory
on its own account.

 

		6.2	During the term of this Agreement, DYAMED agrees that it shall:

 

		(a)	Make Commercially Reasonable Efforts to promote and continue promoting the Product in the Territory, using
techniques and methods admissible and customary for the Marketing of Products in the Field in the Territory;

 

		(b)	Sell and deliver the Product to local customers in the Territory for use in the Field as supplied by SONOMA.
DYAMED shall not modify, alter or add to, or authorize any Affiliate or sub-distributor or other Third Party to modify, alter or add to,
any labelling of any Product without the prior written consent of SONOMA. DYAMED shall only sell the Product unexpired and in good condition;

 

 

    	 	8	 

     

    

 

		(c)	(i) use Commercially Reasonable Efforts to monitor and inform SONOMA as soon as it becomes aware of any
change in the Laws and regulations applicable to the Marketing or Distribution of the Product as well as to the Regulatory Approvals in
the Territory, and (ii) promptly notify SONOMA of any decision from the competent Governmental Authorities to suspend or discontinue the
sale of the Product in the Territory and/or to recall the Product from the market in the Territory;

 

		(d)	Refrain from, and cause its Affiliates and Sub Distributors to refrain from, Marketing and Distributing
any hypochlorous-based product in the Field, regardless of strength or form during the Term of this Agreement and for a period of three
(3) years thereafter.

 

		(e)	Promptly inform SONOMA of any adverse event to the Product occurring in the Territory of which DYAMED
is notified or becomes aware of.

 

		6.3	During the term of this Agreement, SONOMA agrees that it shall:

 

		(a)	Be responsible for all packaging and labelling of Product purchased by DYAMED under this Agreement.

 

		(b)	Provide DYAMED, free of any payment, with such data already in SONOMA's possession relating to the Product
as shall be reasonable for Marketing the Product in the Territory;

 

		(c)	Inform DYAMED of adverse reaction to the Product occurring outside the Territory and known to SONOMA;

 

		(d)	Maintain, during the Term of this Agreement all applicable licenses, permits, authorizations and GMP certificates
necessary to manufacture and sell the Products as provided herein;

 

		7.	PAYMENT and PRICING

 

		7.1	For the right to be the exclusive Distributor for the Territory, DYAMED shall pay to SONOMA USD
                                                           [____] per Contract Year. The first payment of USD [____] shall be due and payable within ninety [_____] calendar days of the
                                                           Effective Date and thereafter Dyamed shall make a payment of USD [____] on each anniversary of the Agreement for the first ten (10)
                                                           Contract Years.

 

		7.2	For each Purchase Order, DYAMED shall pay to SONOMA the prices set out in Schedule 3 hereto, subject to
the adjustment set out in paragraph 7.4.

 

		7.3	If a tariff, tax, duty or other fee (the “Tariff”) is imposed on the delivery any of the Products
to DYAMED, the prices shall increase by the actual cost of such Tariff.

 

		7.4	On each anniversary of the Effective Date, the Parties shall
                                                                                           renegotiate the Product prices within thirty (30) calendar days in good faith. The Product price shall be increased or decreased for
                                                                                           (a) any change in actual cost of goods produced, (b) by the percentage change based on the [____] for the period from the Effective
                                                                                           Date through each subsequent 12 months-period, respectively, and (c) the actual cost of any Tariff or other tax imposed on SONOMA if
                                                                                           not already applied pursuant to paragraph 7.3.

 

 

    	 	9	 

     

    

 

		7.5	All prices are exclusive of any taxes, shipping expenses, and insurance. DYAMED shall pay to SONOMA the
prices by wire transfer within [____] calendar days after each Product delivery date. SONOMA shall have the right to charge DYAMED
interest on late payments. Interest shall accrue at a rate of 5% on an annual basis. Should SONOMA need to take action to collect past
due amounts, DYAMED shall reimburse SONOMA for any actual expenses incurred in the collection, including reasonable attorney’s fees.

 

		8.	INTELLECTUAL PROPERTY

 

		8.1	SONOMA shall be the owner of, and hereby reserves, any and all Intellectual Property rights with respect
to the Product. DYAMED shall properly identify and accurately describe all Product as Product of SONOMA. DYAMED shall not alter, remove,
deface or obscure any Intellectual Property rights or Packaging Material of SONOMA. DYAMED shall not add any trademarks or notice to the
Packaging Material without the prior written consent of SONOMA.

 

		8.2	SONOMA reserves any and all rights that it may have in any of SONOMA’s names, logos and other trademarks
that are included in the Packaging Material of the Product or are otherwise used in connection with the Marketing or Distribution of the
Product.

 

		8.3	DYAMED shall immediately inform SONOMA of any infringement, misuse, misappropriation or violation of any
Intellectual Property right of SONOMA of which it becomes aware. In the event of any such infringement, misuse, misappropriation or violation
relating to the activities of DYAMED, an approved Sub Distributor or any Third Party acquiring Product from DYAMED, DYAMED shall take
all steps reasonably necessary to terminate such infringement, misuse, misappropriation or violation but excluding any right or obligation
to initiate any legal proceedings. SONOMA shall have the exclusive right to commence, prosecute and settle any legal proceedings to enforce,
recover damages on account of or obtain other relief with respect to any infringement, misuse, misappropriation or violation of its Intellectual
Property. In connection with any such legal proceeding in the Territory, DYAMED shall provide such assistance as SONOMA may reasonably
request, including, without limitation, in enforcing any judgment, settlement, award or order; provided that SONOMA shall reimburse DYAMED
for any expenses reasonably incurred by DYAMED to provide such assistance. DYAMED shall not have any right to commence, prosecute and
settle any legal proceedings to enforce, recover damages on account of or obtain other relief with respect to any infringement, misuse,
misappropriation or violation of SONOMA’s Intellectual Property.

 

		9.	TERM and TERMINATION

 

		9.1	This Agreement shall enter into force on the Effective Date hereof and shall continue, subject to the
provisions of this Section 9, for a period of twenty (20) years from the Effective Date (“Initial Term”). The Initial Term
may be extended through written amendments executed between the Parties. Neither Party shall be entitled to make any claim or present
any legal challenge as a result of the expiration or non-renewal of this Agreement under the provisions of this Section 9.1.

 

		9.2	This Agreement shall be subject to early termination:

 

		(a)	by either Party upon advance written notice to the other Party if the other Party is in material breach
of any of its obligations hereunder for reasons other than Force Majeure and, if such breach is curable, fails to remedy such breach at
the end of a period of 60 (sixty) days after receipt of formal notice of breach and demand to cure such breach;

 

		(b)	by either Party upon advance written notice to the other Party if (a) the other Party is placed in voluntary
or compulsory liquidation or falls into bankruptcy or ceases its activities for any reason or (b) the other Party is prevented, in full
or in material part, from performing any of its obligations hereunder for reasons of a Force Majeure Event for a period of 3 (three) consecutive
months or more or (c) for reasons beyond either Party’s reasonable control, the competent Governmental Authorities refuse to renew
the Regulatory Approvals or revoke the Regulatory Approvals or any other license or permit necessary to import, Market or Distribute the
Product in the Territory, or (d) if both parties fail to reach an agreement upon mutually acceptable revised prices for the Product pursuant
to Section 7.4.

 

 

    	 	10	 

     

    

 

		(c)	by SONOMA with immediate effect upon advance written notice,
(i) in the event that DYAMED fails to make purchases of Products at least equal to the Minimum Annual Purchase Amount in any Contract
Year and to make Product purchases equal at least the Deficit Amount in the six (6) months following the end of such Contract Year as
provided in Section 5.1(f); (ii) if two (2) consecutive payments from DYAMED to SONOMA
are delayed by more than thirty (30) calendar days after the due date and such payments are not made within thirty (30) calendar days
of receipt of SONOMA ́s written notice to DYAMED in respect thereto; (iii) in the event that any Governmental Authority takes any
action or raises any objection, that prevents SONOMA from supplying and/or exporting the
Product into the Territory. In this case, before termination, the Parties shall use commercially diligent efforts to remove the objections,
or agree to amend this Agreement; (iv) in the event of any unauthorized use of SONOMA ́s technical information or Confidential Information;
or (v) in the event of a Change of Control of DYAMED.

 

		(d)	by DYAMED with immediate effect upon advance written notice,
(i) at any time upon one hundred-eighty (180) days notice; (ii) in the event two (2) Product deliveries are delayed for more than thirty
(30) calendar days for reasons other than for Force Majeure Event and such delivery is not made within thirty (30) days of receipt of
DYAMED’s written notice to SONOMA in respect thereto; or (iii) in the event any Governmental
Authority takes any action or raises any objection that prevents DYAMED from buying and/or importing the Product in the Territory for
a period longer than six (6) months.

 

		10.	CONSEQUENCES OF TERMINATION

 

		10.1	Upon expiry as well as upon termination of this Agreement, DYAMED shall:

 

		(a)	within six (6) months from the termination or expiration of this Agreement, be entitled to sell all unexpired
Products already delivered to DYAMED as provided in Section 5.2(b) subject to the terms of this Agreement, and cease using any SONOMA
Trademarks immediately upon the earlier of the expiration of such period or the sale of all Product inventory; provided, however, that
if SONOMA terminates this Agreement due to breach of DYAMED’s obligations under Sections 3.1, 3.2 or 12 of this Agreement, DYAMED
shall have no right to continue to sell the Product inventory or to use SONOMA’s Trademarks as licensed in Section 2.4 herein.

 

		(b)	pay SONOMA all amounts related to Purchase Orders placed and not yet paid pursuant to Section 5.1(c);
and

 

		(c)	return forthwith to SONOMA free of charge all documents or records, in whatever media, in DYAMED’s
possession or under its or any of its Affiliates or Sub Distributors’ control, except for digital backups automatically generated
and stored at DYAMED’s servers, containing SONOMA’s Confidential Information, which shall continue to be subject to the confidentiality
and non-use provisions of this Agreement;

 

		10.2	Upon expiry as well as upon termination of this Agreement, SONOMA shall:

 

		(a)	fulfill any outstanding Purchase Order enterd into prior to the termination of this Agreement, unless
the termination is the result of a termination pursuant to Section 9.2(b);

 

		(b)	have the right to repurchase from DYAMED any or all Products held by DYAMED in good condition at a price
equal to the Product purchase price;

 

		10.3	The provisions of Sections 1, 10, 11, 12, 13 and 14 shall survive for a period of five (5) years after
the expiration or termination of this Agreement.

 

		10.4	Except as otherwise specifically provided for in this Agreement, neither Party shall have any liability
(e.g. for any claim of damages, loss of revenue, profit or compensation, for anticipated sales or for any costs, expenses, investments
or other commitments made in reliance upon or otherwise in connection with this Agreement) to the other on account of any expiration or
termination of the Term. Without limiting the generality of the forgoing, neither Party shall have any right, either express or implied,
by applicable Law or otherwise, to renewal of this Agreement or to any damages or compensation for any such termination.

 

 

    	 	11	 

     

    

 

		11.	GOVERNING LAW and SETTLEMENT of DISPUTES

 

		11.1	This Agreement shall be governed by and interpreted in accordance with the laws of the state of Georgia,
except the conflicts of laws provisions.

 

		11.2	Each Party shall use its best reasonable endeavours to settle amicably any dispute which may arise with
the other Party in relation to the construction, performance or termination of this Agreement.

 

		11.3	Any disputes, controversies, doubts or questions between the Parties whether relating to the construction,
meaning, scope, operation or effect of this Agreement or the validity or breach hereof (a “Dispute”) which cannot be settled
amicably shall be finally settled by arbitration by and according to the Rules of Arbitration of the London Court of International Arbitration
(LCIA) by one (1) arbitrator chosen in common agreement between the Parties from the LCIA list of arbitrators. If the Parties does not
reach an agreement within 30 (thirty) days from the notice of arbitration, the LCIA shall be entitled to appoint the arbitrator in accordance
with its Rules. The arbitration proceedings shall be conducted in the English language and the venue of the arbitration shall be the city
of London, England.

 

		11.4	The Parties shall not disclose the arbitration procedure or its object, and shall maintain confidential
all the information directly or indirectly related to the controversy submitted to arbitration.

 

		11.5	The arbitral award shall be given in writing. It shall be binding upon the Parties and shall be enforceable
in accordance with its terms and conditions. The arbitral award can be enforced in any court having jurisdiction on the Parties or on
their assets.

 

		12.	CONFIDENTIALITY

 

		12.1	Receiving Party acknowledges that it received or that it shall receive Confidential Information during
the Term of this Agreement, and that such Information shall be kept confidential by Receiving Party with the same degree of care given
to its own Confidential Information. Receiving Party shall not make use of or disclose the Confidential Information to any third party,
except for the purposes expressly authorized herein or with the express prior written authorization of the Disclosing Party involved.
Confidential Information may be disclosed only to the officers, directors, consultants and employees of the Receiving Party on a need
to know basis, provided that such personnel are advised and subject to obligations of confidentiality as strict as the ones established
herein. Furthermore, Receiving Party is aware that it may be held liable for the acts and omissions of their officers, directors, consultants,
employees or subcontractors.

 

		12.2	Disclosures to Regulatory Authorities as required by Law or necessary to secure the registration, licensing
and commercialization of the Products shall not be deemed as a breach of the confidentiality provisions established herein.

 

		12.3	The obligations of confidentiality and non-use stated in this Section are independent of all other rights
and obligations of the Parties under this Agreement and shall remain in effect beyond the termination, cancellation or expiration of this
Agreement for any reason.

 

		12.4	Receiving Party hereby acknowledges and agrees that any breach of or noncompliance with the confidentiality
obligations stated herein may result in immediate and irreparable harm to Disclosing Party who shall be entitled to pursue any legal measures
and remedies provided under the Law or in equity to prevent or cease the disclosure, as well as to repair any damages and losses.

 

		12.5	Upon termination or expiration of this Agreement, or upon request of Disclosing Party, Receiving Party
shall immediately return all Confidential Information received from Disclosing Party, including, but not limited to, registration documents,
scientific information, publications or any other material deemed confidential, without making or retaining any copies.

 

		12.6	If Receiving Party becomes aware or has knowledge of any unauthorized use or disclosure of Confidential
Information, it shall promptly notify Disclosing Party of such unauthorized use or disclosure and, thereafter, shall take all reasonable
steps to assist Disclosing Party in attempting to minimize any potential or actual damages or losses resulting from such unauthorized
use or disclosure.

 

		12.7	Receiving Party agrees that it shall not claim to have any rights, title or ownership over the Confidential
Information, and that rights, title and ownership over the Confidential Information shall rest in Disclosing Party.

 

 

    	 	12	 

     

    

 

		13.	LIABILITY and INDEMNIFICATION

 

		13.1	DYAMED shall indemnify, defend and hold harmless SONOMA for any action, claim, cause of action, loss,
damage, liability, interest, penalty, cost or expenses (including without limitation, any reasonable costs or legal fees thereby incurred
by SONOMA) arising out of any demands, suits, or actions, to the extent arising or resulting from (i) death, bodily injury or damage to
property caused by any fault or negligence by DYAMED’s employees or agents in the importation, Marketing or Distribution of the
Product in the Territory, or (ii) any breach of DYAMED’s obligations under this Agreement; or (iii) any product claims, representations
or warranties, whether oral or written, made or alleged to be made by DYAMED in its advertising, publicity, promotion or sale of any Product,
where such Product claims or representations were not approved by SONOMA; or (iv) any infringement, misuse, misappropriation or violation
of any Intellectual Property right of SONOMA; provided that SONOMA shall (i) notify forthwith DYAMED of any such claim and (ii) not take
any action or admit any liability or pay any amount to, or compromise with, any Third Party in respect of such claim, except with DYAMED’s
prior consent or in compliance with a court order.

 

		13.2	DYAMED shall not be liable in contract, tort, negligence, breach of statutory duty or otherwise for any
special, indirect, incidental or consequential damages or for any economic loss or loss of profits suffered by SONOMA, including any loss
of prospective sales, investments made or expenses incurred in connection with this Agreement.

 

		13.3	SONOMA shall indemnify, defend and hold harmless DYAMED for any action, claim, cause of action, loss,
damage, liability, interest, penalty, cost or expenses (including without limitation, any reasonable costs or legal fees thereby incurred
by DYAMED) arising out of any demands, suits, or actions, to the extent arising or resulting from (i) breach of any representation or
warranty of SONOMA under this Agreement; or (ii) total or partial recalls of Product; or (iii) any bodily injury or death caused by any
alleged defects in materials, workmanship, or design of Product; provided that DYAMED shall (i) notify forthwith SONOMA of any such claim
and (ii) not take any action or admit any liability or pay any amount to, or compromise with, any Third Party in respect of such claim,
except with SONOMA ́s prior consent or in compliance with a court order. SONOMA’s liability under this Agreement shall be limited
to US$100,000.

 

		13.4	SONOMA will not be liable in contract, tort, negligence, breach of statutory duty or otherwise for any
special, indirect, incidental or consequential damages or for any economic loss or loss of profits suffered by DYAMED, including any loss
of perspective sales, investments made or expenses incurred in connection with this Agreement.

 

		13.5	Each of SONOMA and DYAMED shall maintain a liability insurance that covers Product liability in such amounts
as is advisable pursuant to ordinary good business practices. Each Party shall provide the other Party evidence of this coverage upon
written request.

 

		14.	MISCELLANEOUS PROVISIONS

 

		14.1	This Agreement and its Schedules constitute the entire agreement between the Parties in relation to the
purchase, Marketing, distribution, and sale of the Product in the Territory and supersede all prior oral or written agreements between
the Parties, including, without limitation, the exclusive distribution agreement dated October 20, 2005, relating to the same subject
matter, including without limitation each of the Parties’ general conditions of sale or purchase. No change to this Agreement and/or
its Schedules shall be binding upon the Parties unless it is made in a written document signed by authorized representatives of both Parties
or of their legal successors. Unless otherwise expressly provided in SONOMA’s order acceptance for a particular Purchase Order,
as provided under Section 5 of this Agreement, the terms of this Agreement shall apply to all purchases by DYAMED from SONOMA. Any terms
or conditions proposed by DYAMED inconsistent with or in addition to the terms and conditions in this Agreement shall be void and of no
effect unless and until specifically agreed to in a writing executed by an authorized representative of SONOMA.

 

		14.2	After the Effective Date, each Party may use the other Party’s name(s) and trademark(s) exclusively
in order to issue a press release or public announcement of the Parties’ relationship under this Agreement. DYAMED acknowledges
that SONOMA may make a public announcement and such filings that are required under state and federal securities laws applicable to SONOMA.
SONOMA shall provide the press release to DYAMED for approval, prior to public release and filing. Except for the foregoing, no public
announcement or press release shall be made without both Parties’ prior written consent as to the content of such announcement or
press release.

 

 

    	 	13	 

     

    

 

		14.3	Any notice required to be given by either Party to the other under this Agreement shall be validly given
through overnight carrier, considered delivered after three days from posting, or through electronic mail with receipt confirmation, sent
to the address of the Parties as set out hereafter or to any new address notified to the other Party:

 

i.       If
to SONOMA to the attention of:

 

Bruce Thornton, COO; Address: 645 Molly
Lane, Suite 150, Woodstock, GA 30189, USA

 

ii.      If to DYAMED to the attention
of:

 

Theodore Tan, Director; Address 10
Ubi Crescent #02-41 Ubi Techpark Singapore 408564.

 

		14.4	Should any provision of this Agreement become invalid or unenforceable under applicable Laws, this shall
not invalidate or render any other provision invalid or unenforceable. The invalidated or unenforceable provision shall be deleted and
replaced, by mutual consent of both Parties, by a valid or enforceable provision having the same effect as, or an effect as close as possible
to the effect of the original provision. If such effect is deemed illegal, such clauses shall be eliminated automatically from this Agreement,
without affecting the validity of the Agreement.

 

		14.5	The headings in this Agreement are for information only and will not be considered in the interpretation
of this Agreement.

 

		14.6	This Agreement is made in English and the English text shall prevail over its translation into any other
language.

 

		14.7	Neither this Agreement nor any of the rights or obligations of the Parties may be assigned or sublicensed
without the prior written consent of the other Party; provided, however, that DYAMED may assign it to one Affiliate of DYAMED and that
either Party may, without the consent of the other Party, assign this Agreement or any of its rights or obligations hereunder in connection
with the sale of substantially all its assets; and provided, further, that any transfer or transfers of shares of either Party, or the
merger of a Party with a Third Party, shall not constitute an assignment of this Agreement.

 

		14.8	Any waiver of the terms and conditions hereof must be explicitly in writing and executed by a duly authorized
officer of the Party waiving compliance. The waiver by either of the Parties of any breach of any provision hereof by the other shall
not be construed to be a waiver of any succeeding breach of such provision or a waiver of the provision itself. The delay or failure of
any Party at any time to require performance of any provision of this Agreement shall in no manner affect such Party’s rights at
a later time to enforce the same.

 

		14.9	The relationship between the Parties is that of independent contractors and each Party agrees to conduct
its affairs accordingly. Neither Party shall, by reason of this Agreement, be deemed to be a member of a partnership or joint venture
with the other Party.

 

		14.10	This Agreement shall be binding upon and inure solely to the benefit of the Parties, and their respective
successors and permitted assigns, and nothing in this Agreement, express or implied, is intended to or shall confer upon any Third Party
any right, benefits or remedies of any nature whatsoever under or by reason of this Agreement.

 

		14.11	This Agreement may be executed in two (2) or more counterparts, each of which is to be considered an original
and taken together as one and the same document.

 

    	 	14	 

     

    

 

 

Made on the date hereof in two original copies,
including one for each Party.

 

	Sonoma Pharmaceuticals, Inc.	 	DYAMED BIOTECH PTE LTD.
	 	 	 
	 	 	 
	/s/ Amy Trombly	 	/s/ Theodore Tan
	Name: Amy Trombly	 	Name: Theodore Tan
	Position: CEO	 	Position: Director
	 	 	 

 

 

 

 

    	 	15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}]]